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ABSTRACT 
 
Background: The aim was to review the first twenty trials of the regional CD4 AFREQAS scheme. 
This scheme was implemented to raise awareness of the need for quality laboratory testing and to 
continually improve and maintain a high standard of CD4 enumeration used in support of treatment 
programmes. The overall performance from 2002 to 2006 (Trials 1-20) is reported. 
 
Methods: Commercial stabilised CD4 external quality assessment (EQA) material, both with 
normal and low CD4 values were shipped across 20 trials. Data was analysed for each trial, for 
each participant which included; the trimmed mean, standard deviation, the percent coefficient of 
variation, the residual, and the standard deviation index (SDI) values for both the CD4 absolute 
counts (CD4 abs counts) and CD4 lymphocyte percentages (CD4%Ly). Individual laboratory SDI 
values across 20 trials were analysed according to CD4 methods. The cumulative pooled SDI data 
across 20 trials of subgroups of users, using similar methods were analysed. The overall 
performance of Southern African networks and Grant supported networks were assessed. 
 
Results: Overall CD4 AFREQAS between-laboratory precision (trimmed %CV) was 11.9% and 
10.8% for CD4 abs counts and CD4%Ly respectively. For the respective CD4 abs counts and 
CD4%Ly where normal value material was shipped, trimmed %CV of 10.9% and 8.1% were 
observed, and in low value shipments trimmed %CV of 14.2% and 17.0% were observed. The 
cumulative CD4 abs counts SDI analysis showed the best between-laboratory precision amongst 
BDS FACSCount™ and Panleucogating (PLG-CD4) users (both SD (SDI) =<1.2 and %CV of 
<9%). Single platform algorithm based systems (BDS TruCOUNT™ MultiSET™) and volumetric 
systems (Partec®) showed poorer between-laboratory precision (both SD (SDI) =>2 and %CV of 
>13%). These two systems had more outliers and no submission results than the BDS 
FACSCount™ and PLG-CD4 users. With respect to the African and Grant supported networks, the 
CD4 AFREQAS scheme has highlighted a number of factors that have contributed to poor 
performance which are lack of training and poor service delivery. Investment in additional 
technical training by the service providers and improved service delivery will improve the quality 
of CD4 testing in Africa. 
 
Conclusion: From the inception of CD4 AFREQAS, significant advances have been made in the 
quality control and monitoring of participating national and African laboratories offering CD4 
testing. CD4 AFREQAS has provided a platform for improving the reproducibility of CD4 
reporting both within and between laboratories in South Africa and Africa. With ongoing teaching 
through participant feedback evaluation, and dedicated training programmes, as well facilitating the 
use of standardised laboratory protocols necessary to contain costs, and maintain high standards of 
CD4 testing, there has been a huge impact on establishing excellent CD4 service delivery. 
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 1
1.0   INTRODUCTION 
An external quality assessment (EQA) scheme is designed to provide an independent check of 
laboratory results.  It allows comparison of different methods and instruments for the same test and 
therefore is an assessment of reliability between laboratories.  External quality assessment (EQA) is 
an evaluation by an outside organization of the performance by a number of laboratories on 
specially supplied control samples. The EQA scheme monitors the performance of each laboratory 
over time and identifies those laboratories that require training or corrective action to improve their 
performance. One of the best ways for a laboratory to monitor its performance, against both its own 
requirements and the performance of other laboratories, is to participate regularly in an EQA 
scheme. This testing helps to highlight not only repeatability (same method) and reproducibility 
(different methods for same test) performance between laboratories, but also systematic errors, i.e. 
bias or trends.  
 
Analysis of performance of a laboratory is however, a retrospective exercise and cannot override 
good internal quality control procedures. The EQA provides the laboratory with a snapshot of what 
would have occurred on a “normal” routine day in a laboratory. The objective of an EQA scheme is 
to promote between-laboratory and between-method comparability, whereas, it is the prerogative of 
a laboratory to attain good within laboratory precision. The EQA scheme enables participating 
laboratories to relate their performance to their peers, either nationally or internationally.  
 
Good Clinical Laboratory Practice (GCLP) (1) enables maintaining quality. Good Clinical 
Laboratory Practice encompasses quality control comprising (i) Internal quality control: the 
laboratory uses procedures and reagents recommended by the manufacturers to ensure accuracy 
and reproducibility of the testing system, test by test, day by day and (ii) External quality 
assessment (EQA): an evaluation by an outside organization of the performance by a number of 
laboratories on specially supplied control samples. Quality control is supported by the procedures 
performed with a set of operating procedures to ensure standardization of testing.  
 2
1.1 Background of Current CD4 EQA Schemes 
External quality assessment schemes in flow cytometry play an important role of laboratory testing 
of immune monitoring and testing. In the last twenty years, several EQA schemes were in 
operation in the United States, Canada and Europe with the purpose to improve the accuracy and 
precision of cell identification and testing of lymphocyte subsets and leukaemia/lymphoma 
immunophenotyping. With the outbreak of the acquired immune deficiency syndrome (AIDS) 
epidemic and the need for reliable CD4 testing, scientists and pathologists were given a stimulus to 
develop accurate and reliable methods for enumeration of CD4 cells (2). This led to an increased 
demand for EQA in flow cytometry and initiated a series of multinational collaborative studies (3-
6). Laboratories can benefit from participation in an EQA scheme. It confirms the competency of 
the laboratory,  identifies problems with test methods, monitors participant  improvement of 
performance over time, educates staff,  generates confidence, monitors competency of staff, 
determines  accuracy and precision of test methods and can satisfy local auditing and accreditation 
organisations, depending on the type of scheme used by a laboratory (7). 
 
There are two types of quality assessment schemes available (8, 9): 
1. Proficiency testing (PT) refers to an external quality assessment scheme in which sanctions are 
linked to inadequate performance; for example, a laboratory may be required to repeat testing if 
poor performance is noted on a single trial. These laboratories can however have their accreditation 
status rescinded in the event of ongoing poor performance and they would only be re-instated once 
adequate performance is re-established. This type of assessment scheme is mandatory for all 
laboratories in the United States of America, where all PT schemes are required by law to subscribe 
to the guidelines by the Clinical Laboratory Improvement Act (CLIA) (10-12).  
2. The other type of EQA scheme is an assessment scheme where there are no penalties for poor 
performance and the emphasis is on improving quality of testing through technical support. There 
are many debates about the differences between, and the benefits of educational and regulatory 
EQA schemes. An educational EQA scheme appeals to more participants than a regulatory PT 
scheme. On the downside, because educational EQA schemes are not compulsory or enforced by 
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law, the return of results may be lower compared to participants in regulatory schemes (13). The 
EQA schemes practiced in the Benelux countries and by UK NEQAS are recognized as the model 
best fulfilling participant’s needs and as more effective than the ones run by the Federal Drug 
Administration (FDA) and Centers for Disease Control and Prevention (CDC) in the United States 
(14). The European and United Kingdom EQA schemes are not only regulatory bodies, but also 
play a role in teaching and education (14-16).  
 
Participation in an EQA scheme improves between-laboratory performance and can act as a tool to 
identify problems experienced by the participating laboratory (17, 18). There are several well 
recognized international immune monitoring EQA schemes available for CD4 testing including UK 
NEQAS for Leukocyte Immunophenotyping (www.ukneqas.org.uk), The College of American 
Pathologists (CAP) (19) and HIV Immunology, Health Canada Quality Assessment Scheme 
International (QASI) (www.qasi-lymphosite.ca).  In comparison with their international 
counterparts, relatively few laboratories in Africa (including Sub-Saharan Africa) participate in 
international EQA schemes.   
 
In Africa in 2003, 51% of countries had a national quality assurance programme in place for CD4 
testing, but participation was limited to the main reference laboratories. Further, the World Health 
Organisation (WHO),  reported that EQA testing was conducted at least once a year in 53% of 
African countries in 2003, but only half of these laboratories actually submitted results (20). 
Problems associated with participation include, the high cost of EQA schemes, logistical problems 
with sample transport to testing sites and lack of infrastructure and computers to enter data onto 
websites for submission of results.  In addition, international EQA schemes are frequently 
commercial investments and their focus may not necessarily be the development of quality 
laboratory capacity building in resource-poor settings. Promotion of locally or regionally supported 
EQA schemes would therefore have more impact in Africa if the scheme is run with an 
understanding of regional difficulties and circumstances, methods used and even local languages 
where applicable.  AFREQAS (21) was introduced in 2002 in support of this need and initially 
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underwritten by WHO (22) and later supported through the South African National Health 
Laboratory Service (SA-NHLS) (23). 
 
CD4 EQA schemes have used fresh whole blood and frozen cells, but these schemes are typically 
limited to countries like the USA and Europe, where transport infrastructure could support rapid 
transport of samples to testing sites under temperature controlled conditions.  However, this 
situation is not ideal, as this material can generate wide coefficients of variation (%CV) and 
masked factors that affected a laboratory’s performance (24). To overcome these problems, 
stabilized whole blood products were adapted by some (25, 26) for CD4 EQA schemes but not 
others (27). Use of stabilized whole blood enabled distribution of CD4 EQA material across 
countries and even continents. Further, inter-assay and inter-laboratory performance could be 
compared without being compromised by the instability of fresh samples during shipment and 
storage (25, 26). The disadvantage however, of  stabilized blood is that it is not compatible with all 
types of haematology analyzers or CD4 methods and is therefore not recommended for dual 
platform CD4 analyses where an automated lymphocyte count is required for calculation of the 
absolute CD4 count (14, 28). The use with manual bead assays has also been difficult (29). 
 
1.2 Background to the need to promote CD4 EQA for the Sub-Saharan Region of Africa 
Sub-Saharan Africa remains the region most heavily affected by human immunodeficiency virus 
(HIV) (22 million), accounting for 67% of all people globally living with HIV and for 75% of HIV-
associated deaths in 2007 (30). Estimates of the number of adults and children living with 
HIV/AIDS in South Africa were 5.35 million in 2008 (31). On average 1.9 million new infections 
are reported annually for this region of which most are in the age group 15-24 years. The global 
move to improved universal access to ARV therapy has resulted in major efforts toward making 
therapy cheaper and more readily available to Sub-Saharan Africa, with an estimated 2.3 million 
people on therapy in this region at the end of 2008 (26).  Although financial aid to these regions has 
increased 6-fold since 2001, with $10 billion US dollars spent on treatment and prevention of HIV 
in 2007, relatively little funding has been used to develop laboratory capacity. Although HIV 
 5
incidence seemed to have stabilized globally since 2000, the latest South African prevalence rate of 
HIV infection for the total adult population is 18%, (all age/sex groups) (31). Therefore, South 
Africa has urgently scaled up both HIV prevention and treatment programmes as well as providing 
infrastructure for ongoing monitoring of HIV patients on antiretroviral therapy (32-39).  
 
1.3 The laboratory measurement of CD4 
Although various laboratory tests are available for diagnosis and monitoring of HIV infection 
(rapid testing, ELISA testing and HIV-viral load by PCR) respectively (40), the absolute CD4 T-
cell count has been established as the method of choice to stage and monitor the progression of 
HIV infection (41, 42).  The normal reference interval for healthy adults in South Africa is an 
absolute CD4 count of 500-2010cells/l and a CD4 percentage of lymphocytes of 27-58% (43). 
HIV infection causes a decline in the absolute and percentage CD4 positive cells as the disease 
progresses. Initiation of anti-retroviral treatment is recommended when the absolute CD4 count 
drops to below 350cells/µl, but in South Africa and other resource-poor setting, level of 200cells/µl 
have been advocated (44-46).   
 
CD4 T-cell enumeration methods covers a wide spectrum of technology and skill requirements, 
ranging from simple manual assays (i.e. Dynabeads, TRAx CD4 Assay, Microvolume fluorimetry, 
Beckman Coulter Cytosphere system, Capcellia and dried blood spots) (40, 47-52) at the low end 
to automated flow cytometric testing at the high end of the spectrum (Beckman Coulter, Becton 
Dickinson, Partec) (53-58). 
 
Table 1.1 outlines the different types of CD4 methodologies described for use in Sub-Saharan 
Africa. To date both flow cytometric and manual bead based, requiring a microscope, methods 
have been developed for CD4 enumeration. Typically, manual assays require minimal technical 
skills and flow cytometric systems require more technical skills. Flow cytometry is however 
considered the gold standard/reference method for the enumeration of CD4 counts due to its proven 
accuracy and precision (21, 58-69). Although previously complex, technically demanding, and 
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costly method, it has evolved in recent years driven by the HIV/AIDS pandemic (61) to affordable 
bench-top instruments that can be operated with minimal training and at low running costs (61, 70-
78).  
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 Manual Assays Automated Assays 
Low-medium sample throughput High sample throughput 
Assay and 
Manufacturer 
Coulter® 
Manual CD4 
Count Kit 
Beckman 
Coulter 
Dynal® T4 
Quant Kit 
Invitrogen 
 
 
FACSCount 
Becton Dickinson 
 
Partec CyFlow 
Partec 
 
Pointcare Now 
Pointcare 
Technologies 
Beckman Coulter 
XL (Flowcare, 
PLG/CD4 or 
Tetrachrome  
T-cells) 
Becton Dickinson 
FACSCalibur 
(TruCOUNT 
MultiSET) 
Instrumentation Neubauer 
counting chamber 
and light 
microscope 
Magnet Neubauer 
counting chamber. 
Light/fluorescence 
microscope 
 
Dedicated CD4 Counters 
 
Dedicated CD4 Counters with advanced 
applications available 
Assay Principle Direct observation 
of Bead Rosetted 
Cells 
Direct observation 
of Immuno –
captured cells 
 
Flow Cytometry 
 
Flow Cytometry 
Detection system Latex Beads 
conjugated to  
anti-CD4 
Magnetic beads 
conjugated to anti-
CD4 and CD8 
Fluorochrome 
labelled anti-CD3, 
CD4 and CD8 (3-
color) OR CD4, 
CD14, CD15 (CD4 
test alone) 
Fluorochrome 
labelled anti-CD4 
and CD45 
Fluorochrome 
labelled anti-CD4 
with colloidal gold 
particles 
PLG/CD4 (CD45 and 
CD4 fluorochrome 
labelled antibodies) 
T-cells (CD45, CD4, 
CD3 and CD8 
fluorochrome 
labelled antibodies) 
4-color (CD3/ CD8/ 
CD45/CD4 
fluorochrome 
labelled antibodies) 
3-color (CD3/CD4/ 
CD45 or CD3/8/45 or 
CD4/8/3 
fluorochrome 
labelled antibodies) 
Results Absolute CD4 
count 
Absolute CD4 and 
CD8 counts  
Absolute and % CD4 counts 
Absolute and % CD8 and CD3 counts 
Absolute and %CD4 counts 
Absolute and % CD3 and CD8 counts 
Advantages Simple and rapid Simple and rapid Simple with little operator intervention or skill 
Well quality controlled through both internal and external quality 
control schemes 
Some systems can operate on battery power 
 
Cost efficient for high volume testing 
Instruments have additional applications 
Well quality controlled through both internal 
and external quality control schemes 
Reagents are generally less expensive 
Reagents can be used interchangeably 
between systems 
Disadvantages Subjective 
Low throughput 
No external quality assessment 
programmes available because of the 
specific local methodology. These 
products have been reported as not 
compatible with stabilized blood 
products. 
 
High cost of initial installation and maintenance 
Need good technical support 
Need trained/skilled laboratory staff 
Dedicated with limited applications 
Maximum 50-100 samples per instrument per day 
Reagents relatively expensive 
EQA material cannot be analyzed on all systems 
Have specific reagents and kits tailor made for the instrument 
High cost of initial installation and 
maintenance 
Need good technical support 
Need trained/skilled laboratory staff 
Need good laboratory infrastructure (i.e. 
temperature control, dust free environment) 
Need uninterrupted power supply 
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1.4 Implementing a CD4 EQA scheme for Sub-Saharan Africa (including South Africa) 
 
The aim of this project was to review the first twenty trials of the regional CD4 AFREQAS scheme. 
This scheme was implemented to raise awareness of the need for quality laboratory testing and to 
continually improve and maintain a high standard of CD4 enumeration used in support of treatment 
programmes. 
The aim of this study was sevenfold: 
1. Establish the requirements of implementing a regional EQA scheme including all 
documentation, data collection platform and logistical aspects including transportation and 
methods of result submission and participant feedback. 
2. Establish robustness of a commercial stabilised fixed blood product during the pilot 
initiation for use in subsequent trials. 
3. Establish methods for data analysis of all submitted results and further establish a database 
for analysis of cumulative trial data. 
4. Analyse the participation performance of all users, laboratories and subgroups defining all 
methods used within each trial. 
5. Analyse the cumulative pooled SDI data across 20 trials to assess performance of 
subgroups of users using similar methods identifying deficiencies and outline systems best 
used by African users. 
6. Review participant performance with respect to strengths and common errors, to ascertain 
areas for training initiatives. 
7. Show by example which statistical analysis of comparative data, how intervention post-
poor performance, can positively impact on an individual laboratory’s ability to report 
reliable CD4 counts. 
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2.0  MATERIALS AND METHODS 
2.1  Study design  
This was a retrospective study where results were collected from laboratories in South Africa and 
Sub-Saharan Africa participating in the CD4 AFREQAS scheme. Results of the first 20 shipments 
(29 samples) were collected from July 2002 to September 2006. Absolute CD4 counts (abs counts) 
and CD4 percentage of lymphocytes (CD4%Ly) were statistically analysed for comparison of data 
with each trial and cumulatively across 20 trials. 
 
2.2  Study Participation 
National government CD4 laboratories, university laboratories and private pathology laboratories 
were included in the study.  The CD4 AFREQAS scheme was initially implemented at local level, 
then put into operation at a national level, and finally extended to a regional African level. 
The first CD4 AFREQAS trial was conducted in the Gauteng province, where thirteen laboratories 
from Johannesburg and Pretoria participated. These laboratories were chosen for the initial Trial 1 
study as they performed high volumes of CD4 tests. Prior to participation, the CD4 AFREQAS 
scheme coordinator met with each participating laboratory manager to discuss the aim and benefits 
of the programme. The laboratory managers showed an interest in both internal quality control as 
well as external quality assessment and wanted to improve on their general laboratory performance. 
During the initial site visit, to these and subsequent participants, laboratories were made aware of 
the guidelines and standards available on Good Laboratory Practice (GLP) and Good Clinical 
Laboratory Practice (GCLP) to enable them to introduce GLP into their laboratories (1). 
Participants were further informed that results generated from their laboratories were in the interest 
of patient care, by generating reproducible results, to standardise techniques across centres and 
improve the CD4 laboratory diagnostic service.  
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The aim of CD4 AFREQAS was to provide an assessment scheme (advisory) and not an assurance 
scheme (policing). The CD4 AFREQAS scheme offered assistance to laboratories with regard to 
corrective actions but was not responsible for ensuring implementation of these advised corrective 
actions. 
Following the Trial 1 pilot, Trial 2 was extended nationally and comprised laboratories from 
Bloemfontein, Durban and Cape Town, extending the scheme to a total of 25 participants. Trial 3 
was extended regionally into Africa and laboratories from Namibia, Swaziland, Botswana, 
Mozambique, Angola, Zimbabwe, Senegal, Uganda, Ghana and Burundi participated (n= 44 
participants). By September 2006 (Trial 20), Zambia, Kenya, Rwanda, Nigeria, Cote d’Ivoire, 
Lesotho, Germany and India had also joined the scheme.  
The National Health Laboratory Service (NHLS) enrolled the national network of laboratories on 
the scheme from Trial 6 in 2004. In the first year of CD4 AFREQAS scheme, two trials were sent 
out followed by three in 2003 and four in 2004. From 2005, the frequency of trials sent out 
increased to six times a year, in the first week of every second month in line with the frequency of 
the UK NEQAS Immune Monitoring CD4 scheme (www.ukneqas.org.uk). 
 
2.3  Documentation  
Various documents were generated, both to ensure the success of the scheme and to obtain 
information and data required for this dissertation.  
2.3.1    Registration form for participants 
The registration form was the first form to be developed, as it was important to get clear 
information regarding each participant. The registration form was given to all new participants to 
supply details of a physical address for courier dispatch, a postal address for all correspondence, the 
name of the institution, an email address, phone number and fax number. All demographics on the 
returned registration form were collated into a Microsoft Excel software spreadsheet. As the study 
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progressed and more information became available, Microsoft Excel was not sufficient for data 
management and subsequently all information were transferred into Microsoft Access Software. 
Participation was deemed to be continuous with automatic annual renewal unless the participant 
advised the programme coordinator to the contrary in writing (Appendix B1). 
To protect the confidentiality of each participant on enrolment, a unique participant number was 
assigned to each laboratory that was used across all trials (Appendix B2). 
2.3.2  Certificate of participation 
A certificate of participation on the CD4 AFREQAS scheme was given to participants annually, 
confirming registration and participation on the scheme for that year. Certification did not imply or 
ensure competence of participants as is the case with other international EQA programmes (18, 24). 
(Appendix B3). 
2.3.3  Regional and International documentation 
In addition to the registration form, the following documentation was required for participants 
outside South Africa. 
2.3.4  Safety advice and instructions 
A document was formulated for participants advising on the handling of the CD4 External Quality 
Assessment (EQA) material to be treated as potentially bio-hazardous. The WHO guidelines on 
HIV Safety precautions (WHO/EMC/97.3), as well as recommendations on safety practices in the 
laboratory (79), were distributed with each shipment (Appendix B4). 
 The instruction sheet gave general information on how to process the QC material, record results 
and a deadline was given for return of results (Appendix B5). 
 According to the manufacturer’s instructions, the CD4 external quality assessment (EQA) material, 
which was fixed and stabilised, was to be treated as potential bio-hazardous material and instruction 
sheets carried an appropriate warning. The manufacturer states in the package insert that all blood 
used in the preparation of the EQA material was tested by the Food and Drug Administration (FDA) 
approved method for the presence of antibodies to Human Immunodeficiency Virus (HIV-1, HIV-
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2), Hepatitis C Virus (HCV) and Hepatitis B surface antigen (HbsAg) and found to be negative 
(were not repeatedly reactive) (80). Because no test method could offer complete assurance that 
HIV, HCV, Hepatitis B Virus (HBV), or other infectious agents were absent, the EQA material was 
recommended to be handled at Bio-safety Level 2 as prescribed for any potentially infectious 
human serum or blood specimen.  
2.3.5  Export and Import permits 
The export permit had to comply with the Department of Health Regulation 2 and 3 of GN 2306 of 
21 December 1920. In terms of this regulation, the Department of Health Regulations authorise the 
export of biological substance specimens for External Quality Assessment testing, from the 
Republic of South Africa. These specimens comprised fixed, stabilised (non-infectious) whole 
blood which was to be used in participating laboratories (Appendix B6). 
Although the External Quality Assessment material had no commercial value, a description of the 
goods with a commercial invoice was required for customs purposes. Both the senders address 
(shipper), and recipients address (consignee) had to be stated. The commercial invoice had to be 
signed and dated, and the international courier waybill number entered on the invoice (Appendix 
B7). 
In addition to the local material, stabilised whole blood supplied by Quality Assessment Scheme 
International (QASI), Ottawa, Ontario, Canada was donated for six trials namely; Trial 1, Trial 2, 
Trial 3, Trial 10, Trial 14 and Trial 16. An import permit was required from the South African 
Department of Health for the QASI material which had to comply with the Department of Health 
Regulation 2 and 3 of GN 2306 of 21 December 1920. In terms of this regulation, the Department 
of Health Regulations had authorised the import into South Africa of biological substance 
specimens for the CD4 External Quality Assessment programme. The material comprised fixed, 
stabilised (non-infectious) whole blood that could only be used in the External Quality Assessment 
programme (Appendix B8). 
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2.3.6  Data Report Form 
Participants were given instructions on how to record their results as well as how to complete all the 
information required on the data form. This information was necessary to give a meaningful 
interpretation to the CD4 AFREQAS scheme.  
2.3.6.1  Sample condition 
Participants needed to comment on the sample condition, whether satisfactory or unsatisfactory. If 
the latter, they needed to give a reason (i.e. haemolysed, clotted, insufficient, etc) 
2.3.6.2  Return Date 
A date of submission of results was required to be entered by all participants. 
2.3.6.3  Participant Name and Participant Code number 
The participants were required to record their participant name and the participants’ unique code 
number for identification.  
2.3.6.4  Date of receipt and date of sample analysis  
All participants were required to enter this information.  
2.3.6.5  Antibody Panel Used 
Participants needed to state the antibodies and fluorochrome combination used for CD4 testing as 
different antibodies and fluorochromes express varying levels of fluorescent intensity and are 
known to contribute to inter-laboratory variability (81, 82). 
2.3.6.6  Flow cytometer used  
Participants were given a selection of the instruments currently in use, i.e. BDS FACSScan, BDS 
FACSCalibur, BDS FACSCount, Beckman Coulter FC500, Beckman Coulter Elite, Beckman 
Coulter EPICS XL, Partec, Ortho Cytoron and Other (e.g. Guava). To assess the performance of 
groups of laboratories using the same methodology, it is important to determine which flow 
cytometer methodology is used for CD4 counting. Participants were also requested to give 
information on instrument maintenance and service frequency. 
 14
2.3.6.7  Flow cytometry platform used 
Participants were required to state if the CD4 method used was dual platform or single platform.  
2.3.6.8  Bead product  
Participants were required to state the manufacturer of the bead product used (Flow Count™, 
Beckman Coulter or TruCOUNT™, Beckton Dickinson), if they reported single platform CD4 
counts.  
2.3.6.9  Lymphocyte Count Measurement  
Participants using the dual platform method were asked to state the method used to obtain an 
absolute lymphocyte count. 
2.3.6.10  Pipetting Method 
Participants had to state if they used a manual or automated pipette and also if forward or reverse 
pipetting technique was used. They were asked to supply information on the calibration of pipettes. 
2.3.6.11  Red-cell Lysis  
Participants could choose between a no-wash no-lyse method (e.g. BDS FACSCount™) or a lyse-
no wash method (e.g. ImmunoPrep or FACSLyse).  
2.3.6.12   CD4 gating strategy 
Participants were required to state the gating strategy used to identify CD4+ T-cells at the time of 
each shipment. The laboratory was required to chose the appropriate gating strategies, i.e. (i) 
Lymphocyte gating (FSC/SSC with CD3/4/8); (ii) CD45 bright lymphocytes (abbreviated version 
of CD3/4/8/45 guideline,4 colour panel)(4); (iii) CD45 bright lymphocytes ((abbreviated version of 
CD3/4/8/45 guideline, 3 colour panel)(4); (iv) CD14/45 2 colour panel (6 tube, 2 colour, 1992 CDC 
guidelines) (46) or (V) PLG-CD4 total CD45 (83).  
2.3.6.13   Workload 
Participants were asked to state how many CD4 tests were processed per month in their 
laboratories. 
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2.3.6.14    Result Reporting 
Participants were required to enter abs CD4 counts (CD8 and CD3 were an option but not reported 
in this study) results as cells/µl and CD4%Ly (CD8 and CD3 were an option but not reported in this 
study). NHLS laboratories were also required to submit their raw data for retrospective assessment 
of outlying performance, to identify sources of error and advise appropriate corrective action. 
2.3.6.15    Comments or suggestions  
Participants were given the option to enter comments and/or suggestions regarding the scheme as 
well as ask for advice on certain aspects of CD4 testing.   
 
2.4  Preparation of EQA material for shipment 
2.4.1   CD4 External Quality Assessment material (EQA) material  
In addition to the Quality Assessment Scheme International, Health Canada (QASI) material, 
commercially available fixed, stabilised whole blood products that mimic laboratory whole blood 
CD4 enumeration procedures, were tested for suitability for distribution on the CD4 AFREQAS 
scheme. These products have known white blood cell concentrations and are supplied with 
reference ranges for both T-cell absolute counts (CD4, CD8 and CD3) and T-cell percentages (CD4, 
CD8 and CD3).  The advantages of fixed blood preparations for CD4 EQA include wide 
compatibility with most flow cytometers, capacity to sustain cell integrity at 370C ( important for 
African distribution with no or little temperature control) and the ability to be used with various 
sample-processing procedures, such as lysing, fixing, washing, etc, (26). Initially, three commercial 
fixed, stabilised whole blood quality control products were assessed on Trial 1, namely, Cytocheck 
CD4 Low (Streck Laboratories, Inc), IMMUNO-TROL Normal (Beckman Coulter, Miami, FL) 
and IMMUNO-TROL Low (Beckman Coulter, Miami, FL).  Upon analyses of the results from 
this trial, it was decided to use IMMUNO-TROL Normal and IMMUNO-TROL Low (Beckman 
Coulter, FL) for all subsequent trials. IMMUNO-TROL material was also supplied by QASI and 
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distributed in Trials 1, 4, 6, 10, 14, 17 and 18. On purchasing the CD4 EQA material the longest 
expiry date was requested to ensure the integrity of the samples for the dates of distribution. 
 
2.4.2   Labelling of EQA material for distribution 
EQA material was aliquoted into capped 2ml Sarstedt micro tubes (Biodex,  Johannesburg). Labels 
were printed for each vial of quality control material distributed to participating laboratories, using 
the mini laser label (Avery Dennison Corporation, UK, Berkshire). Labels contained a sequential 
quality assessment number, for example, Trial 1 EQA 01.  
 
2.4.3   Preparation of CD4 EQA material  
The CD4 EQA material was stored at 2-8°Celcius upon receipt from distributors. Care was taken to 
bring samples to room temperature (20-24°Celcius) before aliquoting for distribution. On reaching 
room temperature samples were placed on a Stuart SSL4 mixer (Merck, Halfway House, Gauteng) 
for thorough, gently mixing to avoid no haemolysis. Once mixed, the material was pooled into a 
large sterile container and gently mixed again to ensure uniformity of aliquoted samples. The 
material was visually inspected for haemolysis by checking the plasma to see if it had a clear straw 
colour appearance as this would indicate no haemolysis, haemolysed red cells would give a red 
tinge to the plasma. A dark brown colour could be indicative of bacterial contamination. If material 
showed any discolouration, it was immediately discarded. 
Strict safety procedures were in place for dispensing material in accordance with standard operating 
procedures of the flow cytometry laboratory. All work was carried out in a class II biohazard safety 
cabinet according to the manufacturer’s instructions. A calibrated pipette was used to dispense 1ml 
of well-mixed CD4 EQA material into pre-labelled vials. After dispensing, the vials were capped 
and thoroughly checked for leakages before refrigerated until the dispatch date. 
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2.4.4  Validation of EQA material 
Each batch of EQA material was validated using two CD4 testing methods by the CD4 AFREQAS 
coordinator after dispensing (before dispatch). Both single and dual platform PLG-CD4 
enumeration was performed (79, 83, 84). These results were used to confirm the reference CD4 
values given with the purchased quality assessment material (package insert). The same procedure 
was followed with the supplied QASI assessment material. These methods used a lyse, no-wash 
method (Beckman Coulter T-Q-Prep™ system) for sample preparation and the Epics®XL-MCL™ 
Beckman Coulter flow cytometer for analysis.  
2.4.5  Dispatch of CD4 EQA material  
For Trial 1, the CD4 EQA material was personally delivered by the CD4 AFREQAS coordinator 
(author of the dissertation) to each participant. Thereafter, the delivery of the CD4 EQA material 
was done through a courier service and the existing communication distribution network of the 
National Health Laboratory Service (NHLS). The CD4 EQA material that took longer than four 
days i.e. 4-6 days to be delivered, was sent in cooler boxes to limit temperature fluctuations. CD4 
EQA material that was sent to Burundi, Senegal and Cote d’Ivoire took 4 days to reach their 
destinations. A delivery time of less than four days, that is 2-4 days, was sent at ambient 
temperature (18-22°) to, for example, Botswana, Swaziland, Namibia, Lesotho and Zambia. A good 
working relationship with the courier company was essential for the success of the programme, as 
the CD4 EQA material had to be delivered as quickly as possible to maintain the integrity of the 
material (85). The courier company supplied a daily update on time of delivery to each participating 
site and in this way; the transit time of each CD4 EQA sample was monitored. Table 2.1 gives a 
summary of the CD4 EQA material. 
 18
 
Table 2.1:  Summary of CD4 EQA material dispatch 
 Trial 
number  Dates of sample dispatch QASI AFREQAS Number of samples 
Trial 1 2002 July QASI  2 
Trial 2 2002 October   AFREQAS 2 
Trial 3 2003 July   AFREQAS 1 
Trial 4 2003 September QASI   1 
Trial 5  2003 December   AFREQAS 1 
Trial 6  2004 May QASI   1 
Trial 7  2004 July   AFREQAS 1 
Trial 8  2004September   AFREQAS 1 
Trial 9 2004 November   AFREQAS 1 
Trial 10 2005 February QASI   2 
Trial 11  2005 April   AFREQAS 2 
Trial 12 2005 June   AFREQAS 1 
Trial 13  2005 August   AFREQAS 1 
Trial 14 2005 October QASI   2 
Trial 15 2005 November/December   AFREQAS 2 
Trial 16 2006 January/February  AFREQAS 1 
Trial 17 2006 March/April QASI  2 
Trial 18  2006 May  AFREQAS 2 
Trial 19 2006 July  AFREQAS 1 
Trial 20 2006 September QASI  2 
 
2.4.6  Courier collection  
Once CD4 EQA samples were packed according to the above regulations, the courier company was 
informed and the consignments collected (86). A Monday was the preferred date for countries 
outside South Africa to ensure all participants received their CD4 EQA samples before the 
following weekend, avoiding delays of CD4 EQA samples at customs over the weekend as this 
would compromise the sample integrity. All African participants received their samples between 
two to four days after shipment. Tuesday was the preferred date for the South African distribution 
and the CD4 EQA samples typically reached the laboratories within twenty-four hours of dispatch. 
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2.4.7  Communication of dispatch 
At the beginning of the year each participant was notified in writing of the dispatch dates. However, 
before a trial send-out, all participants were re-notified either by electronic mail (e-mail)/ fax/phone 
to expect sample delivery. 
 
2.5  Compliance with international regulations for transportation and packaging of CD4 
EQA samples 
United Nations (UN) transport regulations were met when shipping CD4 EQA samples (87, 88). 
Biological substance specimens (CD4 EQA material) are assigned to Category B, or Risk Groups 2 
and 3 and must comply with packaging instructions UN code 650 International Aviation Traffic 
Association (IATA safe transport of dangerous goods by air) (89) or Agreement of Dangerous 
goods by road and rail (ADR safe transport of dangerous goods by road and rail), assigned to UN 
code 3373 (90). The IATA air packaging instructions 650 had to be complied with for all air 
distributions in South Africa and Africa, whilst ADR road packaging instructions 3373 had to be 
complied with for all road distributions in South Africa only. Regional and International 
transportation required the relevant export, import permits and commercial pro forma invoices (87-
89) 
2.6  Pilot study to test sample stability 
It was essential to establish the stability of the CD4 EQA material during transportation to the 
participating laboratories. The aim of the pilot trials was to assess the stability of the CD4 EQA 
material at ambient temperature (samples sent to Namibia and UK NEQAS laboratories in 
Sheffield, United Kingdom) and at 2-6°C (sample sent to Senegal). 
In addition, further audits were performed with selected sites where each site received two sets of 
CD4 EQA material and were requested to return one set of material unopened to the NHLS CD4 
reference laboratory. The returned CD4 EQA material was visually checked for haemolysis and 
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bacterial contamination. Samples were analysed by flow cytometry in the NHLS CD4 reference 
laboratory to ascertain that the T-cell subset enumeration was not adversely affected by sample 
transport.  
 
2.7  Statistical analysis of CD4 AFREQAS results 
 Statistics were performed on two levels: (i) individual laboratory statistics and (ii) pooled statistics 
of all participants to assess the success of the EQA scheme. Both sets of statistics are reported to 
participating sites to allow bias estimation and comparison of individual performance against a pool 
of participants.  
2.7.1 Software Packages used for data entry and analyses 
Microsoft Word™, Microsoft Excel TM, Analytical software STATISTIX 8, Graph Pad® Prism 
version 4, were used to generate statistics, graphs, documents, letters and feedback to all 
participating laboratories. 
  2.7.2 Statistical analyses of overall performance of all participants on the scheme 
Each participant’s data was analysed according to international practice (82, 91-93). On receipt of 
all participant data for each trial, CD4 abs counts and CD4%Ly values were entered into an Access 
database. The mean, standard deviation (SD) and coefficient of variation (%CV) was calculated 
automatically by the Access database program for the combined database of all results, and a ±2SD 
limit determined for both CD4 parameters (untrimmed pooled data). Calculations were done in 
parallel on Excel spreadsheets for the first 10 trials. Results that fell outside the ±2SD limit were 
identified and removed as outliers and pool data re-analysed to calculate a pooled trimmed mean, 
pooled trimmed SD and pooled trimmed %CV.  
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2.7.3  Statistical analyses of individual participant results for feedback reports 
Each participant’s residual value and standard deviation index (SDI) was calculated and compared 
to the pooled trimmed results (as described above) to indicate bias. Laboratories identified as 
outliers (outside of ±2SD of the trimmed pool mean) were contacted to troubleshoot and perform 
corrective actions (94). These participants were not allowed to resubmit corrected results.  
 
2.8  Return of data report form 
Participants returned their results either by fax, NHLS internal postal service for NHLS participants 
or by e-mail. After statistical analysis and generation of individual laboratory reports, results were 
posted back to participants. However, this quickly proved inadequate, as the majority of the African 
participants either experienced delays in receiving their reports or did not receive their reports at all. 
This was resolved by sending the report of the previous trial with the subsequent CD4 EQA 
distribution. Participants were notified that a provisional report was available by fax or email if the 
participant needed the report before the next distribution. However, confidentiality was not 
guaranteed by this method of relaying results. Those participants whose results were outside the ±2 
SD range or did not send in a return result were contacted immediately to effect corrective action 
timeously (Appendix B9). 
 
2.8.1 Data capture and analyses of participant Data Report Forms 
All relevant demographic and technical data was captured from the Data Report Forms onto Excel 
TM spreadsheets at first and later onto a Microsoft Access TM database. The participant information 
was used to assess factors that could impact results and result in bias or skewing of data due to the 
number of participants using a specific technique (i.e. SP versus DP) or methodology (i.e. BDS 
FACSCount™ versus PLG-CD4).  The impact of each factor was calculated as the percentage of 
participant’s versus the total group for each of the variables described under Materials and Methods 
2.4.3. 
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2.8.2  Laboratory performance report 
The performance report was the main interface with all the participants. For all trials the data was 
represented in tabular and graphic form.  (Examples of these are given in Figures 2A and 2B). 
(Appendix B10). 
 
2.8.2.1  Tables  
As shown below (Figure 2.1A), the participant performance report included: the participants’ 
laboratory name, the unique participant number, the region of the laboratory, the trial/survey 
number as well as the date of the trial, the lysing protocol, the instrument/flow cytometer and  
monoclonal antibody panel used. 
The summary table of statistics was divided into two columns (Figure 2.1B). The first column 
reports the participant’s results as abs counts and CD4%Ly. The 2nd column reports the results of all 
participants (global pool). The individual participants results reported for the individual participant 
included their reported results, the residual value (submitted result minus trimmed pooled mean 
result), and standard deviation index (SDI) (residual/SD of trimmed mean) with outliers flagged 
>2SD of the trimmed pool mean. The global pooled results reported the number of participants, the 
group trimmed mean value, standard deviation of the trimmed pool mean (SD) [√∑(X1  -  X)2/(N  -  
1)] and percentage coefficient of variation (%CV) [SD/Mean x100]. 
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A: An example of a laboratory’s participation details 
 
 
 
B: An example of a participant’s results 
 
 
 
 
 
 
 
Figure 2.1: Examples of tables used as part of the Laboratory Performance Report to indicate 
(A) participant details and (B) participant results. 
 
CD4 methodologies were not separated and as such a participant’s results were compared to the 
global pooled trimmed results for all methodologies on the scheme. Data was analysed and outliers 
identified and removed (trimmed data). The latter was analysed for mean, SD, %CV and SDI for 
each lymphocyte subset parameter reported. Individual participant results were compared directly to 
the trimmed SDI value, as recommended by international EQA programs (82, 91, 92). 
 
Participant’s results Pooled trimmed global results 
Indicates an 
outlying flagged 
result 
 > ±2SDI 
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2.8.2.2 Graphs 
In addition to a tabled summary of participant’s performance, results were also represented 
graphically (Figure 2.2). This graph represents a summary of SDI values for all participants, to help 
laboratories interpret their own results versus that of the pool. The limits (±2SDI) were highlighted 
to visualise outliers easily. 
 
 
 
 
Figure 2.2 A bar chart depicting the participant laboratory number versus the calculated SDI 
value of individual participants. Acceptable SDI limits indicated (red lines). Outliers are 
pointed out with red arrows. NS = no result submitted. 
 
Further, included in the result sheet was an explanation of how to interpret the graphs for 
laboratories that were not familiar with quality assurance procedures. In this context, as described 
by Lewis, a Standard Deviation Index (SDI) of less than 0.5 denotes excellent performance. A SDI 
between 0.5 and 1.0 is considered satisfactory. A SDI between 1.0 and 1.5 is considered acceptable, 
a SDI between 1.5 and 2.0 is considered borderline and lastly, a SDI of greater than 2.0 requires 
immediate attention and corrective action (85).  
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2.8.2.3   Monitoring own performance 
Participant laboratories were provided with a blank Levey-Jennings wall chart to plot and monitor 
their performance over time (95).  This was sent to the participants to use at their discretion for 
teaching and training purposes.  
 
2.8.3   Feedback 
On joining the AFREQAS programme, participants were made aware of the procedure of feedback, 
identifying problems and the infrastructure in place to assist laboratories with trouble shooting. 
These included training through one-on-one assistance (phone/fax/e-mail) and/or courses, help in 
identifying noted problems, validation of equipment, advice on different technologies and 
guidelines for equipment maintenance and regular service of instruments.  
Participants who had problems with methods, instruments, trouble shooting poor results phoned, 
faxed or emailed the CD4 AFREQAS programme coordinator for assistance. Flow cytometry raw 
data was requested from sites to assist in troubleshooting. 
 
2.9.  Retrospective assessment of serial longitudinal SDI follow-up performance for 
individual participants  
For the purposes of this study, individual SDI performance of laboratories was monitored 
longitudinally by graphically representing the SDI values versus trial number on a radar graph (21). 
These radar plots enabled visual representation of the accuracy and precision of CD4 abs counts and 
CD4%Ly for individual participants.  
The radar graphs depict the longitudinal follow-up of SDI values (Y-axis; range of -3 to +3) versus 
the trial number (X-axis; range of 1-20) (Figure 2.3). Radar graphs allowed visual representation of 
performance during consecutive trials in one snapshot view showing point of enrolment, non-
submission of results or switched to alternative technologies. In addition this type of graph depicted 
improvement or problems in accuracy and precision over time by clearly indicating outliers. 
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The retrospective assessment of longitudinal SDI follow-up performance is also linked to 
demonstrating performance of laboratories with a network of users (e.g. Namibian Institute of 
Pathology national programme). 
 
A: Laboratory with good performance over time       B: Laboratory with inconsistent performance  
             over time 
 
 
 
 
 
 
 
Figure 2.3: Examples of the use of radar graphs to evaluate participant performance over time 
(A and B). The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-
axis. SDI values are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a 
particular laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS 
scheme. The target SDI of 0 (red line) is indicated for comparison of data to the expected target. 
Represents outliers, while         represents non-submission for a particular trial  
 
2.9.1 Statistical analysis of overall precision of participant groups using the same 
methodology over 20 trials 
 
After consultation with a statistician, within each of the twenty trials, separate sub-analyses were 
performed, to assess the between laboratory precision performance of laboratories using the same 
methodology. The most commonly used methodologies were assessed: BDS FACSCount™ 
(Becton-Dickinson, San Jose, California,USA), single platform Panleucogated CD4 (SP PLG-CD4) 
(Beckman-Coulter, Miami, Florida, USA), TruCOUNT™/MultiSET™ CD45 bright gated 
CD3/CD4/CD8 and Primary CD3 gated CD4/8 (Becton-Dickinson, San Jose, California,USA), and 
Partec® volumetric system (Partec®, Munster, Germany).  
For each trial, submitted results for both abs counts and CD4%Ly for the above groups were pooled 
and a mean, SD and %CV calculated to assess accuracy and precision of each group. The 
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longitudinal precision of each methodology group used was analysed (%CV over the twenty trials) 
for both abs counts and CD4%Ly. Comparisons between methodology groups were done using 1 
way ANOVA analysis. These results were plotted on scatter plots using GraphPad Software. 
 
2.9.2 Retrospective cumulative assessment of longitudinal precision of laboratories using 
the same CD4 methodology 
 
Outlier and non submission rates were calculated for each group of users and is shown in Table 2.2. 
 
Table 2.2: Summary of outliers and non-submission, for the 4 major CD4 methods used by 
participants across the first 20 trials of the CD4 AFREQAS scheme. 
  Absolute counts CD4% Lymphocytes 
Methodology 
% 
Outliers 
% Non 
submissions % Outliers 
% Non 
submissions 
BDS FACSCount™ 2.8 9.9 NA NA 
BDS 
TruCOUNT™/MultiSET™  18.6 11.6 13.2 21.4
SP PLG CD4 6.4 5.5 3.4 4.1 
Partec® 32.8 37.8 NA NA 
(NA = not applicable as these methods could not generate a %CD4 of lymphocytes at the time of the study). 
 
To assess the longitudinal accuracy and precision of a group of laboratories using the same CD4 
methodology (e.g. BDC FACSCount™), the standardised individual laboratory SDI values were 
pooled across the first 20 trials and grouped according to CD4 methodology used. Thus a mean 
(SDI) was calculated per user group per trial.  
 
These mean (SDI) values were used in two ways. 
(i) Radar plots show the mean of the pooled SDI values of a group of users, plotted trial by trial of a 
group of participants using the same methodology. (ii) The mean (SDI) values using STATISTIX 8 
software were plotted using GraphPad Prism software in a Gaussian distribution plot. In this pooled 
SDI analysis grouped according to the same CD4 methodology, the calculated mean of the pooled 
SDI’s, i.e., the mean (SDI) reflects longitudinal accuracy within a group of CD4 users. The SD 
(SDI) of the mean of the SDI namely, SD (Mean SDI), reflects longitudinal precision of a group of 
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CD4 users. In this analysis, ideal accuracy mean (SDI) values should be expected to be 0.0 with an 
expected range of -1 to +1. Ideal precision SD (Mean SDI) values should be expected to be 1.0 with 
an expected range of 0.0 to 1.0. Results were plotted as Gaussian distribution graphs for visual 
interpretation with acceptable ranges indicated and outliers identified as values outside these ranges.  
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Figure 2.4: Examples of Gaussian distribution curves used to monitor performance of groups 
of technologies using the same CD4 method. Accuracy is measured as the mean of 
the SDI and precision as the SD of the SDI. Acceptable performance is highlighted in 
green and poor performance in yellow. 
 
2.9.3  Within trial performance of five African laboratory networks and Grant supported 
networks over 20 trials 
Five African countries that participated in the CD4 AFREQAS scheme had an established National 
Network of multiple laboratories for CD4 testing. These included The South African National 
Health Laboratory Service (NHLS), The Botswana National Government Laboratories, The 
Namibian National Institute of Pathology, The Lesotho National Government Laboratories and The 
Zimbabwean National Government Laboratories.  The performance of laboratories participating 
within these national laboratory networks (South Africa, Botswana, Lesotho, Zimbabwe, Namibia) 
were analysed separately to assess accuracy and precision of national CD4 networks.  
In addition to the five National programmes there were two networks with grant support. 
Significant training of personnel in laboratory management, laboratory methodology and principles 
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of good laboratory practice were conducted in these sites. Personnel were also given training in 
South Africa at the National Health Laboratory Service and Witwatersrand based Contract 
Laboratory Service as well through various commercial suppliers.  Network A included laboratories 
in Kenya, Rwanda, Uganda and Zambia (9 sites), while network B included alternative laboratories 
from Kenya, Botswana, Uganda and Tanzania. The purpose of reviewing the performance of these 
groups was to ascertain impact of standardisation (or lack thereof), and further see if performance 
was improved or not, where training and resources were better (i.e. grant supported groups). 
Pooled group mean, SD and %CV’s were calculated and longitudinal performance measured by the 
mean %CV (precision) and mean SDI (accuracy) across 20 trials. Comparisons between groups 
were done using 1 way ANOVA analysis and results represented graphically as scatter plots of 
%CV results of 20 trials. 
 
2.10  Investigation of laboratories with outlying results 
 
This included error identification with appropriate feedback and corrective action investigation 
within a SA-NHLS laboratory and an investigation of an African laboratory with multiple outlying 
results. 
 
2.10.1 Evidence of corrective action 
 
This included error identification with appropriate feedback and corrective action investigation 
within a SA-NHLS laboratory. 
First, an investigation to monitor the longitudinal maintenance of quality through participation on 
CD4 AFREQAS scheme was done. Secondly, an investigation was conducted into a laboratory 
within the NHLS, who encountered errors in the generation of CD4 absolute counts. This required 
the investigation of imprecision of pipetting through the evaluation of flow count rate monitoring  
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Validation of newly established NHLS CD4 laboratories comprised the following: Operator 
pipetting skill validation, instrument precision and accuracy validation and method validation. This 
validation is done by all new staff before moving onto the CD4 bench, to test their pipetting skills 
as well as the accuracy and precision of the pipettes used for the CD4 setup. It may also be used in 
the event of flow count rate discrepancies to eliminate faulty pipettes and/or operator skill as 
possible causes.  
The use of Flow-Count™ (Beckman Coulter™) beads in the NHLS PLG-CD4 protocol is used to 
monitor the performance of the pipetting accuracy for each individual sample. This is a measure to 
ensure accurate quality reporting of the results. The absolute CD4 count is referenced to the beads 
(the calculation of the absolute CD4 count using beads is: CD4 events/bead events x number of 
beads/µl = absolute CD4 count (cells/ µl)). Any inaccurate added bead amount will impact on the 
accuracy of the single platform CD4 result. The NHLS use the flow count rate method for proactive 
quality control. 
Monitoring the instrument performance and pipetting accuracy and precision over time as a quality 
control procedure is possible by plotting the flow count rate data. Monitoring of the flow count rate 
can be used to: monitor new technologist in training, assess the flow cytometer performance and 
assess pipette accuracy after pipette calibration (21, 96-99). 
 
2.10.2 Investigation of a laboratory with multiple outlying results 
To aid implementation of a more reliable technology in an African site with multiple outlying 
results participating on the CD4 AFREQAS scheme.  
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2.10.2.1 Assessment of bias of proposed new technology 
A comparative study between their predicate method (BDS FACSCalibur MultiSET™) versus a 
proposed new technology (BDS FACSCount™) was performed.  For this purpose, both local 
samples (n=43) and a panel of retrospective CD4 AFREQAS EQA samples (n=20) for assessment 
of precision on CD4 abs counts and CD4%Ly for accuracy assessment (May-June 2006). Fresh and 
CD4 AFREQAS samples were prepared and analysed at the site using both the reference instrument 
and the new instrument. The data was sent to the CD4 AFREQAS coordinator for statistical 
comparison. The following statistics were calculated for all parameters tested: 
The minimum, maximum and median values (to indicate range of values included in the study), the 
standard deviation, and % similarity analyses [{a+b}/2}/a] x100, where a represents the 
reference/gold standard methodology and b the test/new methodology) (100, 101) were also done. 
The co-efficient of variation was done on the CD4 AFREQAS samples as well. Results were plotted 
on scatter plots and Bland-Altman analyses done to detect bias (102).  
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3.0  RESULTS 
 
3.1  Study Participation 
 
The CD4 AFREQAS scheme expanded gradually over four year with three phases introduced. 
Phase one was at a local level of participation, phase 2 was at a national level and phase three at a 
regional African level of participation.  
Since the inception of the CD4 AFREQAS in July 2002, the number of participants in the scheme 
had increased from 13 local South African sites to 195 sites (South African and rest of African 
laboratories) by Trial 20 in September 2006, representing an average annual growth rate of the 
scheme of 16.6% (Figure 3.1).  
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Figure 3.1: A graphical representation of the growth of the AFREQAS CD4 quality assessment 
scheme from July 2002 to September 2006 (Trial 1-20). 
 
At the end of Trial 20 there were 195 participants from 20 countries, with full national CD4 
programmes established in 5 countries including (i) South Africa (100 sites of which 40 were 
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NHLS laboratories, and the remainder consisting of academic/university laboratories, non-
government laboratories and privately run laboratories); (ii) Namibia (6 laboratories, of which 5 are 
national government laboratories and 1 private laboratory); (iii) Lesotho (11 national laboratories); 
(iv) Botswana (15 laboratories of which 12 were national government laboratories and 3 private 
laboratories) and (v) Zimbabwe (19 national laboratories). There were an additional 4 countries 
which had a semi-developed network with more than 5 laboratories registered per country. These 
included Zambia, Kenya, Uganda and Malawi. All the remaining participating African laboratories 
comprised 1 to 4 sites/laboratories per country. A German and Indian laboratory joined the program 
due to their affiliation to associated African laboratories. A German mission group requested to join 
CD4 AFREQAS as an honorary participant to facilitate corrective feedback to their mission 
laboratories in Africa that used their Partec® instruments as well as to assess the use of the CD4 
EQA material and the Partec® instruments. The two Indian laboratories joined CD4 AFREQAS due 
to their affiliation with a grant supported group based in South Africa. The United Kingdom 
National External Quality Assessment Scheme (UK NEQAS) joined CD4 AFREQAS as an 
independent individual participant.  
 
3.1.1  Participant Response Rate 
The CD4 AFREQAS scheme had issued 20 trials by the end of 2006, equating to 29 samples of 
which 20 were “normal” CD4 value material and 9 “low” CD4 value EQA materials. The response 
rate, defined as the number of returned results divided by the number of shipped samples multiplied 
by one hundred to obtain a percentage (range 86.0% to 100%), with an average response rate of 
91.9%  was noted (Figure 3.2). A summary of the user’s outlier and participation rates per trial is 
outlined in Table 3.1. (To view breakdown of non submissions and response in groups of 
laboratories using the same CD4 method see Table 3.2). Delivery by courier was highly reliable 
with no non-delivery of samples reported. Average sample non-return rate was 8.1%. 
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Table 3.1:Participant numbers, percentage increase, response rates and outlier rates over trials 1-20.  
Phase Level Trial 
number 
Shipped 
samples 
(n) 
Percent 
increase 
since 
previous 
trial 
Response 
rates 
(%) 
Outlier rates 
(%) 
 
 
 
CD4 abs 
Counts 
CD4%Ly
One Local 1A 13  92.9 7.7 0.0 
  1B   92.9 0.0 7.7 
Two National 2A 25 78.6 100.0 4.0 12.0 
  2B 100.0 4.0 12.0
Three African 3A 44 76.0 100.0 4.2 8.3 
  4A 48 9.1 89.6 7.0 5.4 
  5A 53 10.4 92.5 4.1 2.3 
  6A 74 39.6 100.0 4.1 4.7 
  7A 75 1.3 88.0 3.0 5.5 
  8A 83 10.7 91.6 3.9 6.3
  9A 85 2.4 89.4 5.3 4.8
  10A 95 11.8 89.5 3.5 9.0 
  10B   89.5 3.5 4.5 
  11A 101 5.9 89.1 4.4 7.6 
  11B   89.1 2.3 6.3 
  12B 110 8.9 90.9 3.0 6.5 
  13A 122 10.9 86.1 3.8 4.9
  14A 126 3.3 92.9 6.0 6.6 
  14B   92.9 4.3 7.7 
  15A 144 14.2 89.6 6.2 6.2 
  15B   89.6 2.3 3.1 
  16A 148 2.7 92.6 3.6 4.8 
  17A 156 5.4 93.6 4.8 1.8 
  17B 93.6 4.8 2.7
  18A 161 3.2 91.3 2.0 4.3 
  18B   91.3 3.4 3.5 
  19A 186 15.5 86.6 3.7 4.3 
  20A 195 4.8 92.8 5.5 5.5 
  20B   92.8 5.0 3.1 
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Figure 3.2: The percentage response rate of participants from Trial 1-20, showing a mean of 
91.9%. 
 
3.1.2  The percentage outlier rate  
An outlier was defined as a submitted result falling outside of ±2 standard deviation of the trimmed 
pool mean. The percentage outlier rate of absolute CD4 counts (Abs CD4)  for all trials was 4.1% 
and CD4% of lymphocytes (CD4%Ly) for all trials was 5.6% (Table 3.1). The percentage outlier 
rate for normal CD4 EQA material was 4.5% for abs counts and 5.8% for CD4%Ly. The percentage 
outlier rate for low CD4 EQA material was 3.2% for abs counts and 5.0% for CD4%Ly.  
 
The percentage outlier rate and non submission of the four most commonly used methodologies is 
summarized in Table 3.2 below. 
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Table 3.2: Summary of outliers and non-submission, for the 4 major CD4 methods used by 
participants, across the first 20 trials of the CD4 AFREQAS scheme. 
  Absolute counts CD4% Lymphocytes 
Methodology 
% 
Outliers % Non submissions 
% 
Outliers % Non submissions 
BDS FACSCount™ 2.8 9.9 NA NA 
BDS 
TruCOUNT™/MultiSET™  18.6 11.6 13.2 21.4 
SP PLG CD4 6.4 5.5 3.4 4.1 
Partec® 32.8 37.8 NA NA 
(NA = not applicable as these methods could not generate a %CD4 of lymphocytes at the time of the study). 
 
Overall BDS FACSCount™ and SP PLG-CD4 users showed the least outliers and non submission 
of results across 20 trials with an average of <5% and <7% respectively. The BDS TruCOUNT™ 
MultiSET™ user group showed higher values across twenty trials with outliers and non submission 
of results with an average of <16% and <17% respectively. The Partec® user group had the highest 
outliers and non submission of results across 20 trials with an average of <33% and <38% 
respectively. 
 
3.2  Summary of relevant information from participant Data Report Forms 
3.2.1  Sample Condition 
There was positive feedback on the sample condition. No samples were reported haemolysed, 
contaminated, clotted or insufficient across the 20 trials supporting the stability already described 
(26). 
3.2.2  Submission of Results 
All returned results were received by or before the due date. However, there were a few non 
submissions, mainly caused by technical problems encountered in individual laboratories. 
3.2.3  Antibody Panel Used 
Seventeen percent (17%) used 1 monoclonal antibody. This group included the volumetric Partec® 
based instrument and Guava® EasyCD4 users. Twenty seven percent participants used the PLG-
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CD4 method with Beckman Coulter™ BCXL instruments, using 2 monoclonal antibodies. Eighteen 
percent used 3 monoclonal antibodies. This group comprised of BDS TC/MS Primary CD3 gating, 
BDS FACSCount™, FACScan™ and Beckman Coulter™ systems. Eighteen percent used 4 
monoclonal antibodies. This group comprised of BDS TC/MS CD45 bright gating and Beckman 
Coulter™ Tetra one systems.  
3.2.4  Flow Cytometer used  
Forty six percent (46%) of participants used Beckton Dickinson of which 24% used 
FACSCalibur™ and 22% used FACSCount™ instruments. Forty one percent (41%) of participants 
used Beckman Coulter™ BCXL instruments. Ten percent of participants (10%) used the volumetric 
Partec® based instruments, while the remaining 3% of participants used FACScan™, BC FC-500 
or Guava® EasyCD4. 
3.2.5  Flow Cytometry Platform used 
At Trial 20, ninety three percent (93%) of participants used single platform and 7 percent (7%) used 
dual platform methodology. 
3.2.6  Bead Product Used 
Fifty percent (50%) of participants, used Beckton Dickinson™ technology used FACSCalibur™ 
with TruCOUNT™ beads. Forty eight percent (BDS FACSCount™ users used bead product 
supplied in ready prepared kit). Ninety five percent (95%) of participants who used Beckman 
Coulter™ BCXL instruments used Flow Count™ beads. One percent Beckman Coulter™ FC-500 
used Flow Count™ beads. These percentages were calculated from the information supplied by 
participants across 20 trials. 
3.2.7  Pipetting method 
All BDS FACSCount users™ used automated pipettes. Beckman Coulter™ BCXL, BDS 
FACSCalibur™, Partec®, FACScan™,  BC FC-500 and Guava® EasyCD4 all used manual 
pipetting methods. Sixty percent (60%) of laboratories calibrated their pipettes either once or twice 
a year. 
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3.2.8  Red cell lysis method 
From the information supplied by the participants, seventy seven (77%) percent of participants used 
lyse no wash methods; twenty three percent (23%) used a no wash no lyse method. 
3.2.9  CD4 Gating Strategy 
Gating strategies used by the participants are described in Table 3.3 
 
Table 3.3 Summary of gating strategies used by participants 
CD4 GATING STRATEGY % Participants 
Lymphocyte gating (FSC/SSC with CD3/4/8) 5 
CD45 bright lymphocytes (abbreviated version of CD3/4/8/45 guideline) 10 
CD45 bright lymphocytes (3- or 4 colour panel) 17 
PLG/CD4 total CD45  37 
BDS FACSCount 21
Partec volumetric 10 
 
3.2.10  Workload of laboratory 
Most participants did not state the number of CD4 samples tested per month. Feedback was not 
forthcoming from laboratories citing confidentiality constraints. 
 
3.3  Assessment of CD4 EQA material  
In Trial 1, two different commercial EQA materials were evaluated, by distribution to 13 
participants on Trial 1 to ascertain which product was most suitable for future trials. The products 
assessed were IMMUNO-TROL™ Normal and Low (Beckman Coulter, Miami, FL) and Cytocheck 
CD4 Low (Streck Laboratories, Inc). These results of this analysis are shown in Table 3.4. 
 
 39
Table 3.4: Commercial EQA material 
  ABSOLUTE CD4 COUNTS CD4 % OF LYMPHOCYTES
Immuno-Trol™ Beckman Coulter, Miami, FL
Trial number Pool mean SD %CV N(labs) Pool mean SD %CV N(labs)
1A 604.9 60.8 10.1* 13 48.3 11.5 23.9 13
1B 146.8 28.4 19.3 13 16.0 8.3 51.9* 13
 Mean %CV 14.7 Mean %CV 37.9 
Precision performance using same material
Cytocheck CD4 Low Streck Laboratories, Inc
QC A 223.6 68.1 30.5* 13 16.1 7.8 48.3* 13 
QC B 231.2 76.5 33.1* 13 16.2 8.5 52.6* 13 
 Mean %CV 31.8  Mean %CV 50.5  
(* Outlier >±2SD identified, but not removed for statistical analysis) due to the low number of 
participants. This outlier identified came from a laboratory that incorrectly reported CD4%Ly of T 
cells instead of the required CD4% of lymphocytes. 
 
Outliers were identified, but not removed from this pilot study according to the Dixon “Q”- test for 
removal of outliers on small sample number (103). Tighter between-laboratory precision was 
demonstrated with Immuno-Trol™ Normal and Low. A mean %CV of 10.1 for IMMUNO-TROL 
Normal and 19.3% for IMMUNO-TROL Low absolute CD4 counts were found vs. a mean %CV of 
31.8% for Cytocheck CD4 Low control. Similar results were obtained for the CD4% of 
lymphocytes, with a mean %CV of 23.0% for IMMUNO-TROL Normal and 51.9% for IMMUNO-
TROL Low vs. 48.3% and 52.6% for CytoChecks CD4 controls (Table 3.4). 
The Cytochecks CD4 controls were not used after this initial pilot study as Immuno-Trol controls 
showed better overall precision between laboratories and were deemed to be the better product for 
distribution, in line with previously published works (26). 
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3.4 Pilot study to test sample stability 
 
Table 3.5: A summary of trimmed SDI values for CD4 abs counts and CD4%Ly stability of 
EQA material at ambient temperature and 2-8°C 
CD4 AFREQAS Pooled Trimmed SDI Results 
  Abs counts  CD4%Ly 
Site Method Pre audit Audit Pre audit Audit 
Senegal (2-8°C) BDS FACSCount 0.2 0.2   
UK NEQAS 
(ambient temp) SP PLG/CD4 0.9 1.1 0.5 0.6 
Namibia 
(ambient temp) SP PLG/CD4 0.3 0.4 0.4 0.8 
 
As shown above, transport and temperature did not affect EQA material stability in this audit.  
Samples tested at ambient temperature were in transit for 7 days (South Africa to the UK NEQAS 
laboratories in Sheffield, United Kingdom and back to South Africa NHLS CD4 reference 
laboratory), while samples shipped to Namibian laboratories and back to South Africa NHLS CD4 
reference laboratory, took 5 days at ambient temperature. Samples to Senegal at 2-8°C took 14 
days. 
 
Additional audits were performed with selected sites where each site received two sets of CD4 EQA 
material and were requested to return one set of material unopened to the NHLS CD4 reference 
laboratory (n=46 samples tested). 
Good accuracy and precision for abs counts and CD4%Ly was reported in keeping with the first 
audit. The mean abs counts noted to be 642 pre-shipment versus 643 post shipment, with a mean 
CD4%Ly 45.3 values noted both pre and post shipment (Figure 3.3).  
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Figure 3.3: Comparison of CD4 abs counts and CD4%Ly used for sample stability audit study 
at ambient temperature. 
 
3.5  Assessment of overall performance of all participants on the AFREQAS scheme 
A summary of the statistical analyses of trimmed pooled data for all participants (irrespective of 
methodology used) is shown in Table 3.6. 
Over the twenty trials, the trimmed mean %CV (between laboratory precision) for CD4 abs counts 
was 11.9%, ranging between 7.4% (Trial 13A) to 22.7% (Trial 4). The trimmed mean %CV 
(between laboratory precision) for CD4%Ly was 10.8% ranging between 4.4% (Trial 20A) to 
51.9% (Trial 1B). For the normal level CD4 EQA material, the trimmed mean %CV (between-
laboratory precision) for CD4 abs counts was 10.9% and 8.1% for CD4%Ly. For the low level CD4 
EQA material analysis, the trimmed mean %CV (between-laboratory precision) for CD4 abs counts 
was 14.2% and 17.0% for CD4%Ly. Overall the participating laboratories showed poorer precision 
(%CV) with “low” material than with “normal” material for both CD4 abs counts and CD4%Ly. 
Accuracy was however relatively consistent between normal and low EQA material. Some trials 
(1A, 1B, 4, 5, and 15B) showed poorer accuracy and precision but were not removed from the final 
analysis. Specifically, the results for Trial 1 were included despite small participant numbers (and 
that data was not trimmed). Removing these trials from analyses, the %CV for the normal material 
absolute CD4 changed to 9.9% and normal CD4%Ly to a CV of 7.2%. For the low EQA material, 
the %CV for CD4 abs counts stayed at 14.2% while the CD4%Ly CV changed from 17 to 12.6%.   
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Table 3.6: Within trial performance of CD4 AFREQAS participants trimmed results of all 
methodologies, showing precision between participants. 
 ABSOLUTE COUNT CD4% OF LYMPHOCYTES 
Trial number Mean SD CV 
Participant 
(n) Mean SD CV 
Participant 
(n) 
1A 604.9 60.8 10.1 13 48.3 11.5 23.9 13 
1B 146.8 28.4 19.3 13 16.0 8.3 51.9 13 
2A 609.3 66.2 10.9 25 41.7 2.2 5.3 25 
2B 527.9 55.0 10.4 25 43.2 2.7 6.2 25
3 624.5 84.1 13.5 48 45.8 3.0 6.6 46 
4 662.0 150.4 22.7 43 45.0 5.9 13.1 37 
5 657.9 111.5 16.9 49 44.1 3.8 8.6 43 
6 568.4 54.9 9.7 79 45.0 2.2 4.9 64 
7 588.0 49.1 8.4 66 45.2 2.8 6.2 55 
8 620.1 68.3 11.0 76 48.2 3.7 7.7 64
9 631.8 55.4 8.8 76 49.0 6.2 12.7 62 
10A 626.0 60.1 9.6 85 43.8 2.2 5.0 67 
10B 160.3 15.4 9.6 85 35.3 4.7 13.3 67 
11A 637.2 52.8 8.3 90 44.9 2.5 5.6 66 
11B 137.2 19.6 14.3 88 19.7 2.2 11.2 64 
12B 163.8 20.0 12.2 100 34.8 3.3 9.5 77
13A 590.4 43.6 7.4 105 43.0 3.7 8.6 81 
14A 496.9 52.9 10.6 117 42.2 4.5 10.7 91 
14B 146.2 20.9 14.3 117 18.5 2.1 11.4 90 
15A 481.7 49.4 10.3 129 42.2 4.2 10.0 97 
15B 144.0 24.4 16.9 128 19.1 4.3 22.5 96 
16A 536.7 48.4 9.0 137 43.9 2.8 6.4 104
17A 537.0 44.4 8.3 146 40.1 1.8 4.6 111 
17B 146.5 11.7 8.0 145 21.3 2.1 9.7 110 
18A 515.8 59.8 11.6 147 40.3 2.2 5.5 115 
18B 141.7 19.1 13.5 146 21.0 2.2 10.5 114 
19A 529.7 55.2 10.4 161 40.3 2.2 5.5 115 
20A 685.4 67.7 9.9 181 45.0 2.0 4.4 127
20B 128.5 25.8 20.0 179 18.9 2.4 12.8 127 
Mean 449.9 50.9 11.9  37.4 3.6 10.8  
(*Shaded cells indicate trials with higher trimmed %CV) 
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Figure 3.4: Comparison of SD (1A and 1B) and %CV (2A and 2B) values of the first 20 CD4 
AFREQAS trials for both normal and low material, with no outliers removed. Each 
dot represents either trimmed SD or %CV from a single trial. 
 
3.6:  Summary of overall performance of all participants 
Participant performance was characterised as excellent, good, and intermediate or poor based on the 
number of outliers and non-submissions. Excellent performers had neither outliers nor non 
submissions during their time of participation. Good performers had 2 or less outliers/non-
submissions, intermediate performers had 3-5 outliers/non-submissions and poor performers more 
than 6 outliers/non-submissions for the duration of their participation on the CD4 AFEQAS scheme. 
For intermediate and poor performing laboratories, a percentage improvement over time was 
calculated to assess if CD4 AFREQAS intervention had a positive effect on EQA results. 
 
1A 1B
2A 2B
 44
Table 3.7: Summary of the overall performance of individual participants and percentage 
improvement noted post input from CD4 AFREQAS scheme 
Performance of total participants across twenty trials
 Outliers and non 
submissions
Absolute counts CD4 % Lymphocytes 
Excellent None 35.8% 40.6% 
Good < 2 30.8% 32.4% 
Intermediate 3-5 21.4% 13.0% 
Poor ≥ 6 11.9% 14.0% 
 
3.6.1  Performance of laboratories reporting CD4 absolute counts 
Overall, 35.8% of participants show excellent serial continued performance across 20 trials. Here 
the methodologies used comprised mostly SP PLG-CD4 and BDS FACSCount™ users. A single 
laboratory using the BC Tetrachrome™ four colour test was also included in this group. 
A second group of users defined as good performers comprised a further 30.8%. Here, 
methodologies used including BCI Tritest™ primary CD3 gated, BDS FACSCount™ and SP PLG-
CD4 users. 
The third group of users, with 3 to 5 either outlying or non submitted results, comprising 21.4%. 
Users of BDS TC/MS and Partec® dominated this group. 
Also the fourth and final of poor performers comprising 11.95% consisted of laboratories using 
mainly BDS TC/MS and Partec® systems. A single laboratory using DP Primary CD3 gating also 
performed very poorly and was included in this group. Of note, was the performance of the 
Zimbabwean group (see section on performance of National programmes), where limited reagents, 
maintenance and in some instances local politics, severely hampered adequate participation on 
performance. 
 
3.6.2  Performance of laboratories reporting CD4%Ly 
Overall, 40.6% of participants show excellent serial continued performance across 20 trials. Here 
the methodologies used comprised mostly SP PLG-CD4 users. A single laboratory using the BC 
Tetrachrome™ four colour test was also included in this group. 
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A second group of users defined as good performers comprised a further 32.4%. Here, 
methodologies used including BCI Tritest™ primary CD3 gated and SP PLG-CD4 users. 
The third group of users, with 3 to 5 either outlying or non submitted results, comprised 13.0%. 
Users of BDS TC/MS dominated this group. 
Also the fourth and final of poor performers comprising 14.0% consisted of laboratories using 
mainly BDS TC/MS systems. A single laboratory using DP Primary CD3 gating also performed 
very poorly and was included in this group. Of note, was the performance of the Zimbabwean group 
(see section on performance of National programmes), where limited reagents, maintenance and in 
some instances local politics, severely hampered adequate participation on performance. 
 
To assess whether after in the groups defined as intermediate and poor performers, a further 
analysis of the group was undertaken. 
In the group with intermediate performance, majority showed random as opposed to consecutive 
outliers, 65% participants, after serial outliers or non submitted results, showed improvement with 
time in this group. 
In the group defined as poor performers, once again, the majority also showed random as opposed 
to consecutive outliers. Here only 25% of participating laboratories showed improved performance 
during Trials 17 to 20. 
 
3.7 Assessment of individual participant results 
3.7.1 Assessment of feedback reports  
 
Figure 3.5 Feedback report 
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For each participant the residual value (difference between participant result and pooled trimmed 
mean) was calculated. Here a negative value implies that the participant was reading lower than the 
pool mean, while a positive residual value indicated that the participant read higher than the pooled 
mean. In Figure 3.5 above, the participant showed a negative residual for both CD4 abs count and 
CD4%Ly. 
The standard deviation index (residual/SD of trimmed mean expressed as a ratio) in the example 
above were outside the acceptable ±2SDI limit (as indicated by the asterix). A flagged result 
automatically raised a need for a corrective action for the laboratory concerned. 
 
3.7.2  Retrospective assessment of serial longitudinal SDI follow-up performance of 
individual participants  
The results below are examples of good versus a poor performing laboratory (irrespective of 
methodologies used) for the first 20 CD4 AFREQAS trials. Radar graphs (e.g. Figure 2.3 materials 
and methods) were generated to view serial longitudinal performance for each participating 
laboratory to identify outliers (>±2SDI), non-submissions of results where technology was 
switched. These graphs enabled graphic representation of laboratories showing good consistency 
and accuracy (Figure 2.3A) of CD4 abs count and CD4%Ly reporting. These radar graphs also 
showed poor accuracy and precision (Figure 2.3B). Due to confidentiality and objectivity and to 
ensure that all technologies were reflected fairly, no pre-selection of individual participant graphs 
are represented in this study. However, selected examples were used to illustrate problems (refer to 
section Appendix D, Supplementary data on troubleshooting and performance of individual 
laboratories).  
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3.8 Assessment of  precision of participant groups using the same single platform 
methodologies within individual trials 
For each trial, the %CV was plotted (Y-axis) against the trial number (X-axis) per methodology 
used. For trial 1 and 2, only BDS TruCOUNT™ MultiSET™ was performed as a single platform 
test. Dual platform methodologies (7% of total participants) were insufficient and excluded from 
this comparison. Single platform PLG-CD4 and BDS FACSCount™ users started to participate 
from trial 3 onward, while Partec® joined the scheme from trial 8. 
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Figure 3.6: Between laboratory precision of laboratories using the same CD4 methodology for 
CD4 absolute counts over 20 trials. 
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Figure 3.7: Between laboratory precision of laboratories using the same CD4 methodology for 
CD4%Ly  over 20 trials. BDS FACSCount™ and Partec® methodology cannot report CD4%Ly. 
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Figure 3.8: The average precision (mean %CV of 20 trials) of laboratories using the same 
methodology, split into normal and low levels of EQA material. BDS FACSCount™ 
and Partec® methodology cannot report CD4%Ly. 
 
3.8.1  BDS FACSCount™ methodology 
Across the twenty trials, the performance of the BDS FACSCount™ participants (comprising 22% 
of participants) for CD4 abs counts showed consistently good performance(BDS FACSCount™ 
users could not report a %CD4 of lymphocytes)  (Figure 3.6 and 3.8). The overall mean precision 
(%CV) was 6.0%. In trials where normal CD4 value material was shipped a trimmed mean %CV of 
5.8% was recorded and trials where low CD4 value material was shipped, a trimmed mean %CV of 
6.4% were noted. Poor precision was only noted in Trial 5 where a %CV of 61.8% was recorded for 
abs counts. This was due to a single outlier where one participant reported a CD4 abs count of 
908cells/µl (pool mean 657.8 cells/µl). On removing this outlying result (DIXON Q-test of outliers 
applied), within this group the trimmed mean for all BDS FACSCount™ users was 657.8 with a 
%CV reduced to 0.9%CV.  
Although BDS FACSCount™ users could not report a CD4%Ly, 7.2% of BDS FACSCount™ 
users incorrectly reported a CD4% of T-cells in place of the CD4% of lymphocytes.  Such incorrect 
values were submitted for trials 2, 3, 5, 10-18 but in most instances, the participating BDS 
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FACSCount™ users understood the difference post intervention and did not repeat the error. 
However, these errors did not significantly impact the overall performance of CD4% Ly. 
 
3.8.2  BDS TruCOUNT™/MultiSET™ methodology 
Across the twenty trials the performance of participants that used the algorithm based BDS 
MultiSET™ system did not perform as well as the counterparts BDS FACSCount™ participants 
(comprising 24% of participants) (Figure 3.6 to Figure 3.8).  
The overall mean between-laboratory precision (%CV) across twenty trials for both normal and low 
EQA material tested in laboratories using TruCOUNT™ MultiSET™ CD45 bright gated 
CD3/CD4/CD8 (TC/MS) showed a %CV of 22.4% and 33.3% for CD4 abs counts and CD4%Ly 
values respectively. In trials where normal CD4 value material was shipped a trimmed mean %CV 
of 18.7% and 27.3% for CD4 abs counts and CD4%Ly values respectively. In trials where low CD4 
value material was shipped, a trimmed mean %CV of 30.7% and 46.6% for CD4 abs counts and 
CD4%Ly values respectively were noted.  
Becton Dickinson manufactures two TruCOUNT™ Multiset™ CD4 enumeration kits; CD4/8/3 and 
CD3/8/45/4. Participants that used the latter, with CD45 bright gating, performed better (%CV of 
14%) than participants that used a primary CD3 (CD3/CD4/CD8) gating protocol (21.4%). 
Laboratories using TC/MS and Primary CD3 gating showed an overall (all EQA material tested) 
%CV of 21.4% and 41.7% for abs counts and CD4%Ly respectively. In trials where normal CD4 
value material were shipped a trimmed mean %CV for absolute CD4 counts and CD4 % of 
lymphocytes was 18.3% and 34.3% respectively. Low CD4 value material showed a %CV for 
absolute counts and CD4 % of lymphocytes was 28.3% and 58.0% respectively. In this group many 
participants incorrectly reported the CD4% of T-cells (CD3) instead of the CD4% of lymphocyte 
values. These transcription errors outliers impacted negatively on the overall precision of the 
MultiSET™ users group with respect to their CD4%Ly reporting. Participants using TruCOUNT™ 
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MultiSET™ generally showed worse performance with low level material regardless of gating 
strategy used.  
 
3.8.3  Single platform Panleucogated CD4 (SP PLG-CD4) methodology 
Across 17 (Trial 3-20) trials the performance of laboratories using the SP PLG/CD4 participants 
showed consistently good performance (comprising 37.9% of participants) (Figure 3.6 to Figure 
3.8).. Single platform PLG-CD4 was introduced into the NHLS from 2004 (Trial 3). Prior to this, 
PLG-CD4 was done as a dual platform method across three sites.  Analysing the performance of 
laboratories using SP PLG-CD4, the overall mean %CV (precision) between laboratories was 8.5% 
and 4.3% for CD4 abs counts and CD4%Ly values respectively.  In trials where normal CD4 value 
material was shipped a mean %CV was 8.2% and 4.2% CD4 abs counts and CD4%Ly values 
respectively. Where low CD4 EQA material was used a mean %CV was 8.8% and 5.4% CD4 for 
abs counts and CD4%Ly values respectively. Some participants (1.7%) incorrectly reported the 
%CD4 of the white cell count (%CD4 of PLG) instead of the required %CD4 of lymphocytes. 
However, these errors did not significantly impact the overall performance of CD4% of 
lymphocytes for this group. 
 
3.8.4  Partec® methodology 
Across 12 trials (Trial 8-20) the performance of laboratories using the Partec® methodology 
showed consistently poor performance (comprising 10% of participants) (Figure 3.6 and 3.8). Over 
the 12 trials of participation, a mean %CV (precision between laboratories) of CD4 for abs counts 
was 26.6%. Laboratories using the Partec® methodology are unable to generate CD4% of 
lymphocytes, nevertheless it generates a %CD4 of T-cells (CD3), similar to BDS FACSCount™. 
This value is however not the relevant clinical value typically required.  Some Partec® users 
incorrectly reported CD4% of T-cells. However, on Trial 18, with corrective action feedback, this 
error was not repeated on subsequent trials. In trials where normal CD4 EQA material was shipped, 
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mean %CV (precision between laboratories) of 29.1% was recorded. Likewise, where low CD4 
value material was shipped a mean %CV (precision between laboratories) of 22.6% was noted.   
 
3.9  Retrospective cumulative assessment of longitudinal precision of  laboratories using 
the same CD4 methodology 
To compare performance between groups using the same CD4 methodology, individual laboratory 
SDI values were pooled across 20 trials and grouped according to methodology used. Separate 
analysis were performed overall and for normal and low EQA material data. All submitted results 
(including outliers) were used.  
Within each group of CD4 users the first analysis plots the Mean SDI, trial by trial, in a radar plot 
distribution (Figure 3.9) The four main methodologies (BDS FACSCount™, BDS TruCOUNT™ 
MultiSET™ and SP PLG-CD4 and Partec®) are used in this analysis. 
The second analysis plots these same Mean SDI values but instead in Gaussian distribution to view 
the spread of the data within each group of participants using the same methodology. Gaussian 
distribution graphs to reflect cumulative accuracy and precision of testing. Gaussian distribution of 
the Mean (SDI) values gives an indication of overall accuracy, whilst the spread of the data reflects 
precision i.e. the SD (of the Mean SDI). For the purpose of this analysis, once again the three most 
commonly used methodologies (BDS FACSCount™, BDS TruCOUNT™ MultiSET™ and SP 
PLG-CD4) were assessed (Figures 3.17 to 3.21). Partec® was not used for the Gaussian distribution 
plots as there was not enough data to generate meaningful plots. 
 
3.9.1  Radar plots showing a group of participants using the same methodology 
To assess the longitudinal accuracy and precision of a group of laboratories using the same CD4 
methodology (BDS FACSCount™, BDS TruCOUNT™ MultiSET™ and SP PLG-CD4 and 
Partec®), the standardised individual laboratory SDI values were pooled across the first 20 trials 
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and grouped according to CD4 methodology used. Thus a mean (SDI) was calculated per user 
group per trial.  
Radar plots show the mean of the pooled SDI values of a group of users, plotted trial by trial of a 
group of participants using the same methodology. 
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Figure 3.9: Radar plots illustrating the longitudinal performance (SDI) or the 4 most commonly 
used CD4 methodologies used across the first 20 trials. A= BDS FACSCount™, 
B= BDS TruCOUNT™ MultiSET™, C= SP PLG-CD4 and D= Partec®) users. 
SDI values are plotted for both the absolute CD4 count (Blue) and %CD4 of lymphocyte 
values (Green) (BDS FACSCount™ and Partec® systems were not able to generate 
CD4%Ly). 
 
3.9.2  Overall methodology comparisons 
In this pooled SDI analysis grouped according to the same CD4 methodology, the calculated mean 
of the pooled SDI’s, i.e., the mean (SDI) reflects longitudinal accuracy within a group of CD4 
users. The SD (SDI) of the mean of the SDI namely, SD (Mean SDI), reflects longitudinal precision 
of a group of CD4 users. Ideal accuracy mean (SDI) values should be expected to be 0.0 with an 
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expected range of -1 to +1. Ideal precision SD (Mean SDI) values should be expected to be 1.0 with 
an expected range of 0.0 to 1.0. Results were plotted as Gaussian distribution graphs for visual 
interpretation with acceptable ranges indicated and outliers identified as values outside these ranges.  
On comparing absolute CD4 counts (Figure 3.10), BDS FACSCount™ and SP PLG-CD4 showed 
similar longitudinal patterns of accuracy and precision. BDS TruCOUNT™ MultiSET™ showed 
poorer overall accuracy and precision with more variability in results (spread) compared to either 
BDS FACSCount™ or PLG-CD4 groups. 
BDS TruCOUNT™ MultiSET™ and SP PLG-CD4 methodologies were compared for CD4%Ly 
(BDS FACSCount™ technology could not produce a CD4% of lymphocytes at the time of the 
study).  SP PLG-CD4 showed better accuracy and precision then BDS TruCOUNT™ MultiSET™ 
showed acceptable accuracy, though with a wider spread (variability) of data. Their precision 
showed that ±50% of the calculated SD of SDI’s was >1 (poor performance). Overall precision for 
PLG-CD4 showed 4 trials with variability (>1) indicating poor performance for these trials (Figure 
3.11). 
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Figure 3.10 Summary of Gaussian distribution curves showing longitudinal accuracy (mean 
SDI, Ci) and precision (SD of mean SDI), Cii) for CD4abs counts between 
technologies. Green areas represent the acceptable limits for both Mean SDI and SD of 
(mean SDI) values, while yellow areas indicate values outside the acceptable limits. Ideal 
values for both mean SDI (0) and SD of (mean SDI) (1) are indicated. 
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Figure 3.11: Summary of Gaussian distribution curves showing longitudinal accuracy (mean 
SDI, Ci) and precision (SD of mean SDI), Cii) for CD4%Ly between technologies. 
Green areas represent the acceptable limits for both Mean SDI and SD of (mean SDI) 
values, while yellow areas indicate values outside the acceptable limits. Ideal values for 
both mean SDI (0) and SD of (mean SDI) (1) are indicated. 
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3.9.3  BDS FACSCount™ methodology 
Pooled SDI data reflecting longitudinal accuracy and precision across 20 trials showed that 
laboratories using BDS FACSCount™ could consistently generate accurate and precise absolute 
CD4 counts irrespective of whether normal or low value EQA material was used (Figure3.12).  
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Figure 3.12: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) 
and precision (SD of mean SDI), Aii and B ii) for BDS FACSCount™ users for 
CD4 abs counts. Green areas represent the acceptable limits for both Mean SDI and SD 
of (mean SDI) values, while yellow areas indicate values outside the acceptable limits. Ideal 
values for both mean SDI (0) and SD of (mean SDI) (1) are indicated. 
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The distribution curves were tight and majority of results indicated good longitudinal accuracy and 
precision for absolute CD4 counts (in green area, Figure 3.12 above). Only one trial showed poorer 
accuracy and precision (Trial 2). This was due to two outliers where one participant reported CD4 
abs counts for both EQA samples (Trials 2A and 2B) of 939cells/µl (pool mean 604.9 cells/µl) and 
870cells/µl (pool mean 609.3 cells/µl) respectively. On low EQA material, the longitudinal follow-
up showed good accuracy (mean SDI) but very slight poorer precision than with normal EQA 
material. This however did not impact on the overall good performance of this methodology on the 
CD4 AFREQAS scheme.  
 
3.9.4  BDS TruCOUNT™ MultiSET™ CD45 bright gating methodology 
Longitudinal accuracy and precision across 20 trials showed that laboratories using TruCOUNT™ 
MultiSET™ CD45 bright gating methodology, indicated acceptable accuracy (green area Figure 
3.13), but demonstrated larger variability (spread of data) for both CD4 abs counts and CD4%Ly 
values for normal and low EQA samples. Precision between laboratories was not ideal, with 50% of 
calculated SD of their SDI values, falling in the range of 1-2 (i.e. poorer performance, yellow area, 
Figure 3.13). Lack of precision of pipetting was the main contributing cause here. Generally, this 
group of users was not able to reliably generate CD4%Ly values consistently. The between 
laboratory precision within most trials was poor (largely contributed by the inability to manually 
gate CD45+ bright populations). 
However, although the overall performance of this technology was poorer than the BDS 
FACSCount™ user group, the individual performance of some laboratories using this system was 
nevertheless excellent (see Appendix D) (104). 
Further, in some trials, the group performance was also better (see Figure 3.9 B, trials 6-11B when 
reporting CD4 abs counts and trials 13A-16A en reporting CD4%Ly values). 
 59
Mean(SDI)
-2 -1 0 1 2
0
1
2
3
4
5
6
7
Group mean Ideal mean
A-i
Ideal range
Fr
eq
ue
nc
y 
of
 r
es
ul
t
SD(SDI)
0 1 2 3
0
2
4
6
Ideal SDGroup SD
A-iiIdeal range
Fr
eq
ue
nc
y 
of
 r
es
ul
t
Mean(SDI)
-2 -1 0 1 2
0
1
2
3
4
5
6
7
Ideal and group mean
B-i
Ideal range
Fr
eq
ue
nc
y 
of
 r
es
ul
t
SD(SDI)
0 1 2 3
0
1
2
3
4
5
6
7 Ideal SD
Group SD
Ideal range
Fr
eq
ue
nc
y 
of
 r
es
ul
t
TruCount MultiSet: Absolute CD4
Normal value material
Low value material
Accuracy Precision
 
 
Figure 3.13: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) 
and precision (SD of mean SDI), Aii and B ii) for TruCOUNT™ MultiSET™ 
CD45 bright gating users CD4 abs counts. Green areas represent the acceptable limits 
for both Mean SDI and SD of (mean SDI) values, while yellow areas indicate values outside 
the acceptable limits. Ideal values for both mean SDI (0) and SD of (mean SDI) (1) are 
indicated. 
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Figure 3.14: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) 
and precision (SD of mean SDI), Aii and B ii) for TruCOUNT™ MultiSET™ 
CD45 bright gating users for CD4%Ly. Green areas represent the acceptable limits for 
both Mean SDI and SD of (mean SDI) values, while yellow areas indicate values outside the 
acceptable limits. Ideal values for both mean SDI (0) and SD of (mean SDI) (1) are 
indicated. 
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3.9.5 SP PLG-CD4 methodology 
Longitudinal accuracy and precision analyses across 20 trials showed that laboratories using SP 
PLG-CD4 could reliably generate accurate and precise CD4 abs counts and CD4%Ly values for 
both normal and low value EQA material. The distribution curves (Figure 3.15) were tight and good 
longitudinal accuracy shown for absolute CD4 counts for normal and low EQA samples analysed. 
Overall precision of the PLG-CD4 group was acceptable for the CD4%Ly (with majority of trials 
Mean SDI <1) (Figure 3.16), although there was more variability (spread of data) on the low EQA 
material compared to normal data. 
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Figure 3.15: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) 
and precision (SD of mean SDI), Aii and B ii) for SP PLG-CD4 users CD4 abs 
counts. Green areas represent the acceptable limits for both Mean SDI and SD of (mean 
SDI) values, while yellow areas indicate values outside the acceptable limits. Ideal values 
for both mean SDI (0) and SD of (mean SDI) (1) are indicated. 
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Figure 3.16: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) 
and precision (SD of mean SDI), Aii and B ii) for SP PLG-CD4 gating users for 
CD4%Ly. Green areas represent the acceptable limits for both Mean SDI and SD of 
(mean SDI) values, while yellow areas indicate values outside the acceptable limits. Ideal 
values for both mean SDI (0) and SD of (mean SDI) (1) are indicated. 
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3.10  Within trial precision of Southern African laboratory networks. 
Five countries with a National programme for CD4 testing participated on the CD4 AFREQAS 
scheme. These included South Africa National Health Laboratory Service (SA-NHLS), Botswana 
National Government Laboratories, Namibia National Institute of Pathology (NIP), Lesotho 
National Government Laboratories and Zimbabwe National Government Laboratories. SA-NHLS 
enrolled their National laboratories using SP PLG-CD4 on the program from Trial 6 in 2004. 
Botswana enrolled one site on the scheme from Trial 3 in 2003 and later enrolled eleven 
laboratories from Trial 15 in 2005 onwards. Namibia enrolled one site on the scheme from Trial 6 
in 2004 and a further four of their laboratories from Trial 10 in 2005. Lesotho enrolled eleven 
laboratories from Trial 14 in 2005 and Zimbabwe enrolled one site from Trial 17 in 2006 and 
eighteen laboratories from Trial 19 in 2006 onwards (Table 3.8).  
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Table 3.8: The precision between laboratories on the same national program is reflected as the 
%CV of the submitted data (Figures 3.17-3.18). 
 Methodology used Total number of 
participating 
laboratories 
Total number of 
laboratories using 
described 
methodology 
Percentage 
laboratories using 
described 
methodology 
South Africa 
National 
Health 
Laboratory 
Service 
Single platform 
Panleucogated CD4 (SP 
PLG-CD4) 
40 40 100 
Botswana 
National 
Government 
Laboratories 
BDS TruCOUNT™ 
MultiSET™ CD45 bright 
gating 
12 4 33 
BDS FACSCount™  6 50 
Unknown  2 17 
Namibia 
National 
Institute of 
Pathology 
Single platform 
Panleucogated CD4 (SP 
PLG-CD4) 
5 5 100 
Lesotho 
National 
Government 
Laboratories 
BDS TruCOUNT™ 
MultiSET™ CD45 bright 
gating 
11 3 27 
Partec®  8 73 
Zimbabwe 
National 
Government 
Laboratories 
BDS TruCOUNT™ 
MultiSET™ CD45 bright 
gating 
19 1 5 
BDS FACSCount™  4 21 
Partec®  4 21 
Dual platform 
MultiSET™ Primary CD3 
gating 
 5 26 
BDS TruCOUNT™ 
MultiSET™ Primary CD3 
gating 
 1 5 
Unknown  4 21 
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3.10.1  Overall performance of Southern African laboratory networks  
South African NHLS laboratories showed the most consistent performance across their course of 
participation on the CD4 AFREQAS scheme, with a mean %CV of 7.99±2.6 for CD4 abs counts 
and a mean %CV of 4.8±2.4 for the CD4%Ly. No outliers were detected for this group. The 
Namibian laboratories also showed consistency in results, with results from one trial (Trial 17B) 
removed as an outlier (%CV of 49.7%). For Trial 17B, only three participants submitted results 
with one result recorded as an outlier. The high %CV was due to a single outlier where one 
participant reported a CD4 abs count of 183cells/µl (pool mean 141.7 cells/µl). Overall they showed 
a mean %CV of 12±11.7% for CD4 abs counts and 4.6±2.8 for CD4%Ly. Botswana laboratories 
showed acceptable (with trial 15B as outlier removed) precision with a trimmed mean %CV of 
10.9±8.7 for CD4 abs counts and 8.45±4.36 for CD4%Ly. However, the inconsistency of 
performance was reflected in the increased SD of 8.7 (spread of data) compared to SD of 2.6 and 
5.5 for South Africa and Namibia respectively (Figures 3.17-3.18 and Table 3.9). 
Lesotho laboratories had mean %CV values of 31±11% for CD4 abs counts, indicating poor 
precision between laboratories of this network. Similar performance in the reporting of CD4%Ly 
was reflected by the mean %CV of 9.4±8.5, indicating inconsistency (poor precision) over their 
period of participation on the CD4 AFREQAS scheme. 
Zimbabwean laboratories had mean %CV values of 38%. On removing three outliers (Trials 9, 13A 
and 20B), the mean %CV for CD4 abs counts decreased to 14.9±12.8%, still indicating a wide 
spread of data and inconsistency of precision. Their %CV for CD4%Ly was 15.9±19.2, again 
indicating poor ongoing precision. In a sub analysis of the BDS FACSCount™ user group (4 
participants), this group had a %CV (<8%) comparable to the reported BDS FACSCount™ user 
group (Figure 3.6). 
 
 
 
 67
Absolute CD4 Counts
South Africa Botswana Namibia Lesotho Zimbabwe
0
20
40
60
80 Upper acceptable limit
CV of 10%
Mean
Std. Deviation
South Africa
7.992
2.588
Botswana
16.39
19.16
Namibia
12.07
11.70
Lesotho
31.15
11.28
Zimbabwe
21.64
20.14
%
C
V
 
Figure 3.17: Between laboratory precision (%CV) of network laboratories reporting absolute 
CD4 counts  
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Figure 3.18: Between laboratory precision (%CV) of network laboratories reporting CD4 % 
lymphocytes  
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Table 3.9: Comparison of statistics for laboratory precision (%CV) of Southern African 
Network laboratories for CD4 abs counts and CD4%Ly, with outliers and outliers 
removed. 
Absolute CD4 counts South Africa Botswana Namibia Lesotho Zimbabwe 
All data 25.0 10.0 15.0 12.0 20.0 
Mean 8.0 16.4 12.1 31.2 21.6 
Std. Deviation 2.6 19.2 11.7 11.3 20.1 
Outliers removed   1.0 1.0   3.0 
Mean   10.9 9.4   15.0 
Std. Deviation   8.7 5.5   12.8 
CD4% of Lymphocytes South Africa Botswana Namibia Lesotho Zimbabwe 
All data 25.0 7.0 16.0 9.0 12.0 
Mean 4.8 12.0 4.6 9.4 15.9 
Std. Deviation 2.4 10.2 2.8 8.5 19.2 
Outliers removed   1.0   1.0 2.0 
Mean   8.5   7.3 8.1 
Std. Deviation   4.4   6.3 6.5 
 
 
3.10.2 Analysis of performance between Southern African laboratory networks for normal 
versus low EQA material 
   
As shown in the graphs below (Figure 3.19), the SA-NHLS laboratories showed consistent 
precision for CD4 abs counts and CD4%Ly using the SP PLG-CD4 method regardless of the level 
of EQA material analysed.  Botswana only showed better overall precision on low EQA material for 
CD4%Ly. Namibia showed poor precision on low EQA material for CD4 abs counts. Lesotho 
showed better overall precision on normal EQA material for CD4%Ly. Zimbabwe showed poorer 
precision for CD4 abs counts and CD4%Ly regardless of the level of EQA material analysed 
(Figure 3.19 and Table 3.10). 
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Figure 3.19: Mean %CV reflecting precision between Southern African laboratory networks for 
all shipments grouped according to normal and low EQA material analysed. 
 
Table 3.10: Summary of normal versus low EQA material precision for Southern African 
Laboratory networks. 
CD4 abs 
counts South Africa Botswana Namibia Lesotho Zimbabwe 
  Normal Low Normal Low Normal Low Normal Low Normal Low 
Mean 7.6 8.9 11.8 23.4 7.3 19.2 28.6 34.7 26.2 14.8 
CD4%Ly South Africa Botswana Namibia Lesotho Zimbabwe 
  Normal Low Normal Low Normal Low Normal Low Normal Low 
Mean 4.6 5.4 7.7 17.7 3.8 5.6 7.5 11.8 13.7 19.1 
 
3.10.3  Longitudinal Analysis of individual National networks 
 
Representative examples of the national networks’ (shown in Figures 3.20-3.24) longitudinal SDI 
follow-up performance assessments over the twenty trials were graphically represented to show 
accuracy and precision. Radar (circular) plots of SDI values were used to assess ongoing 
performance of individual laboratories, within a network to help identify problems. 
 
3.10.3.1  South African National Health Laboratory Service (SA-NHLS) 
The SA-NHLS laboratories showed consistent good performance across all the trials they 
participated in (from trial 3 onward). A representative selection of longitudinal performance for this 
group is shown in Figure 3.20. Occasional outliers (examples A, B, C, E and F) and one non-
submission of results (example F) are indicated in the examples below. The overall performance of 
the group was however not adversely affected by isolated laboratory problems (Figures 3.17-3.18). 
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Examples of laboratories that reported the CD4% of WBC instead of the correct CD4%Ly on one 
trial, is shown in Figure 3.20 A and B. Laboratory B and H, had incorrect gating by cutting off the 
CD4 population on the CD4/SS plot and submission of incorrect CD4 abs counts, on one trial. An 
example of a laboratory (C) that had an outlying result for CD4 abs counts and CD4%Ly on Trial 6 
and to ensure correct CD4 abs counting, with further corrective action feedback this participant 
improved on their pipetting skills (See section 3.11, Investigation of laboratories with outlying 
results, Figure 3.28). Examples of laboratories that showed consistently good performance across 
all trials is shown in Figure 3.20 D and G. Majority of the laboratories on the NHLS network 
performed very well. This good within network performance is largely attributed to the fact that the 
South African NHLS standardised their methodology across all laboratories to the SP PLG-CD4 
method (84). SA-NHLS further applied a proactive approach to training by maintaining quality 
between laboratories through the implementation of simplified PLG- CD4 testing, as well as 
through a novel internal quality control system using bead count rates with SP PLG-CD4 method 
(84, 98) and participation on the CD4 AFREQAS scheme (21). These findings are confirmed on the 
within trial precision analysis (Radar mean (SDI) plots Figure 3.9 and Gaussian distribution plots 
Figures 3.10-3.11 and 3.15-3.16). 
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Figure 3.20: South African (National Health Laboratory Service National Programme). SDI 
values obtained from representative SA-NHLS laboratories (A-H) using SP PLG-
CD4. The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI 
values are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
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3.10.3.2  The Botswana National Government Laboratory network 
In January 2002, Botswana introduced their ARV roll-out program. Initially, one laboratory joined 
the CD4 AFREQAS scheme in June 2003, with 8 more laboratories joining in November 2005.By 
July 2006 there were a total of twelve laboratories from Botswana participating. 
The Botswana National Government Laboratory Programme did not use a standardised method for 
CD4 testing or implement a national training programme (Table 3.8). Majority of laboratories used 
the BDS FACSCount™ (n=6) which gave precise and accurate results. The remaining laboratories 
used the BDS TruCOUNT™ MultiSET™ system according to the supplier’s recommendations. 
Despite this, performance was inconsistent and generally poor. Two participants that did not state 
which technology they used. However, the BDS FACSCount™ user group within this Botswana 
network showed reliable and reproducible performance (Figure 3.21). This is shown on the radar 
SDI performance of longitudinal representative participants of the Botswana group (Figure 3.21 A-
D). 
Botswana joined the scheme from Trial 15 and to make the selection for example more 
representative, Trials 21 to Trials 33 were include. In Figure 3.21 examples of laboratories 
performance are shown. These laboratories (A and B) using BDS FACSCount™ showed 
consistently good performance across trials. The non submissions (A-D) had problems with 
procurement and down time of the BDS FACSCount™.  Laboratory E, F, G and H generated 
outlying results with SDI values of >3.0 as well as non submission of results. In communication 
with Laboratory E and H, it transpired that they had experienced problems in getting additional 
training on their instrument and software applications.. Subsequently, these sites received additional 
training from BDS on their instrument and software applications. Since Trial 20 their performance 
has improved dramatically reflecting the impact of appropriate interventions. Some laboratories 
showed no improvement despite corrective action advice. 
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In consultation with Laboratory F and G it was revealed they had their FACSCalibur serviced and 
the staff received technical training. However, these two sites did not improve on their performance 
on subsequent trials.  
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BDS FACSCount™  users A-D 
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Figure 3.21: Botswana National Network laboratories (A-H).   
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
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3.10.3.3  The Namibia National Institute of Pathology (NIP) 
The Namibia NIP had standardised the PLG-CD4 methodology across five national health 
laboratories. These laboratories showed overall reliable and reproducible results, following 
implementation and rollout of their national anti retroviral treatment programme. Analysis of their 
performance requires bead rate monitoring. Introduction of bead count rates (4, 5, 6) was 
recommended to monitor poor pipetting techniques (imprecision and inaccuracy) and improve 
within sample internal quality control. Initially, the participating laboratories had received intensive 
training from Beckman Coulter, South Africa and a follow-up CD4 PLG workshop from the NHLS 
CD4 Reference laboratory but there was no formal NIP training programme. In Figure 3.22 (A-E), 
examples are shown of laboratories within this network. These laboratories showed consistently 
good precision on CD4%Ly. However, the precision was more erratic on CD4 abs counts.  
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Figure 3.22: Namibia National Institute of Pathology laboratories (A-E).   
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
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3.10.3.4  The Lesotho National Government Laboratory network 
In 2005, Medecins Sans Frontiers (Doctors without borders), the Ministry of Health and Social 
Welfare and the Global fund, launched a joint programme in Lesotho to provide antiretroviral 
treatment at the primary health care level to HIV/AIDS patients. In October 2005, eleven 
laboratories enrolled on the CD4 AFREQAS scheme. The Lesotho National programme did not 
standardise (Table 3.8) on a CD4 methodology across the laboratories. BDS TruCOUNT™ 
MultiSET™ incorporating CD45 bright gating was used in three of the eleven laboratories while the 
remaining 8 sites used Partec® instruments.  
The poorer performance of the Lesotho national network is similar to other networks using non-
standardised testing.  Across the trials the poor performance is reflected by a wide variation of 
results submitted. The performance of laboratories using BDS TruCOUNT™ MultiSET™ with 
bright gating showed a wide variation of submitted results and this is shown on the graphical radar 
SDI performance of representative participants (Figure 3.23 A-B). Contributing problems included 
poor understanding and application of the automated algorithm software especially related to gating 
and manual identification of relevant populations, poor pipetting resulting in inaccurate volumes of 
blood being pipetted and calibration of pipettes not monitored. The performance of the Partec ® 
users was especially poor. Although more than 75% of laboratories used one methodology, the 
impact of standardising methodology has been lost due to poor manufacturer support and 
instrument maintenance. Training, to ensure consistency of accurate and precise reporting was 
lacking for pipetting, calibration of pipettes, no basic training on maintenance and repair to improve 
the down time of their Partec ® instruments. 
Examples of BDS TruCOUNT™ MultiSET™ incorporating CD45 bright gating user group are 
shown in Figure 3.23 A and B. These participants joined the CD4 AFREQAS scheme from Trial 14 
and from this trial to Trial 20 demonstrated poor performance with respect to both CD4 abs counts 
and CD4%Ly results. This is reflected by the high number of outlying results (>3.0) and non 
submission of results. These two participants did not respond to suggested corrective action 
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interventions. Examples of the Partec® user group are shown in Figure 3.23 C-H. These 
participants demonstrated poor performance with respect to CD4 abs counts. This is reflected by the 
high number of outlying results (>3.0) and non submission of results. These sites also did not 
respond to suggested corrective action interventions. 
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BDS TruCOUNT™ CD45 bright gating  users A-B 
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Figure 3.23: Lesotho National Government laboratories (A-H).   
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while       represents non-submission for a particular trial  
 
3.10.3.5  The Zimbabwean National Government Laboratories 
In March 2006 (Trial 19), one of Zimbabwe’s largest referral hospitals joined the CD4 AFREQAS 
scheme. In July that year, eighteen national district hospital laboratories also joined the programme. 
No standardised CD4 methodology is used in this network (Table 3.8), with laboratories using 
either BDS TruCOUNT™/MultiSET™ with bright gating, Primary CD3 gating, dual platform 
Primary CD3 gating, Partec® or BDS FACSCount™ methodology.  
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Zimbabwe joined the program from trial 19 and to make the selection for example more 
representative, Trials 21 to Trials 33 were include. In Figure 3.24 examples of laboratories 
performance are shown. 
The poorer performance of the laboratories as a group comprising the Zimbabwean national 
network is similar to other networks using non-standardised testing.  Here poorer precision and 
accuracy is reflected not only by the non standardised testing but also in poor understanding of the 
use of systems used most notably both the BDS TruCOUNT™ MultiSET™ and Partec® 
volumetric base methodologies. The performance of laboratories using BDS TruCOUNT™ 
MultiSET™ system showed a wide variation of submitted results (Figure 3.24 D-F). Once again, as 
had occurred in other sites and networks monitored in this study, the laboratories demonstrated 
poorer precision and accuracy. Contributing problems included poor understanding and application 
of the automated algorithm software especially related to gating and manual identification of 
relevant populations, poor pipetting resulting in inaccurate volumes of blood being pipetted, and 
calibration of pipettes not being monitored. The performance of the Partec instrument® participants 
also showed poor performance in spite of perceived national monitoring in their local Zimbabwe 
National Quality Assessment Programme (Figure 3.24 G-H). Contributing problems included poor 
pipetting, calibration of pipettes not monitored, no training on maintenance and repair of 
instruments to improve the down time of their Partec ® instruments and erratic supply of reagents 
and expired reagents. For improved performance in Zimbabwe, CD4 AFREQAS has recommended 
standardising on technology and securing improved and perhaps additional supplier support into the 
country.  
Of note however, and in stark contrast is the excellent performance of those four sites in the 
Zimbabwe network using the BDS FACSCount™ CD4 system. Here the mean precision (%CV) 
across these three sites, across relevant trials of participation averaged at   <8% seen elsewhere in 
other programmes (Within trial precision analysis (Radar mean (SDI) plots Figure 3.9 and Gaussian 
distribution plots Figures 3.10 and 3.12) 
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The results submitted by BDS FACSCount™ users namely, Laboratories A, B and C were well 
within the 2 SD limits. However across all trials there was a high rate of non submission of results 
due to down time of the instruments. The poor performance of the TC/MS system group of users, 
Laboratories D, E and F is reflected by the high number of outlying results (>3.0) and non 
submission of results. Laboratory F enrolled on CD4 AFREQAS at Trial 19 and submitted only one 
result across all subsequent trials. The performance of the Partec ® users Laboratory G and H was 
especially consistently poor. There was a high non submission rate and this was due to down time 
of their Partec ® instruments.  The performance in particularly of the Partec ® users also reflects 
the importance of manufacturer support for instrument maintenance.  
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BDS FACSCount™ users A-C 
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Figure 3.24: Zimbabwian National Government Laboratories National Program.   
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
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3.10.3.6  Performance of grant supported networks 
In addition to the five National programmes there were two networks of laboratories which were 
grant supported. Significant training of personnel in laboratory management, laboratory 
methodology and principles of good laboratory practice were conducted in all the sites. Personnel 
were also given training in South Africa at the National Health Laboratory Service and 
Witwatersrand based Contract Laboratory Service as well through various commercial suppliers. In 
contrast to other African networks (with the exception of SA-NHLS), these networks performed 
better. 
The performance of these network groups is reflected in the precision (trimmed %CV) across 
twenty trials (Figure 3.25). Selective examples of the performance within these groups of 
laboratories are shown in (Figures 3.26-3.27). A summary of methodologies used in these grant 
based networks can be seen in Table 3.12.  
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Figure 3.25: Between laboratory precision (%CV) of 2 grant network laboratory groups. 
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Table 3.11: Summary of methodologies used in grant supported networks 
 Methodology used Total 
number of 
participating 
laboratories 
Total number of 
laboratories 
using described 
methodology 
Percentage 
laboratories 
using 
described 
methodology 
Grant support 
Network 
group “A” 
BDS FACSCount™ 9 7 78 
BDS TruCOUNT™ MultiSET™ 
CD45 bright gating 
 1 11 
BDS TruCOUNT™ MultiSET™ 
Primary CD3 gating 
 1 11 
Grant support 
Network 
group “B” 
BDS TruCOUNT™ MultiSET™ 
CD45 bright gating 
9 2 22 
BDS FACSCount™  7 78 
 
Overall across both networks, fourteen (14/18) used BDS FACSCount™ and 4 used BDS 
TruCOUNT™ MultiSET™ methodology. The performance of the grant “A” network was worse 
(%CV of 22.7% and 32.4% for CD4 abs counts and CD4%Ly respectively), compared to grant “B” 
(%CV of 7.8% and 16.6% for CD4 abs counts and CD4%Ly respectively) (Figure 3.25 and Table 
3.12). 
 
Table 3.12: Comparison of performance of all and normal versus low EQA material precision 
for Grant supported networks. 
CD4 abs counts Grant A network Grant B network 
  Normal Low Normal Low 
All mean %CV 22.7  7.8  
Mean %CV 12.7 35.1 7.8 12.6 
CD4%Ly Grant A network Grant B network
  Normal Low Normal Low
All mean %CV 32.4  16.6  
Mean %CV 33.4 30.1 11.7 24.1 
 
Within the Grant supported network groups, in general the low EQA material presented higher 
variability in results, as reflected in poorer precision (%CV) (Table 3.12). 
 
3.10.3.6.1 Grant supported laboratory network A 
From August 2003, grant supported laboratory network A was distributed across four countries 
including Kenya, Rwanda, Uganda and Zambia. The methodologies used by this group consisted of 
BDS TruCOUNT™ MultiSET™, one group using CD45 bright gating and other using Primary 
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CD3 gating to identify CD4 T cells and a third group using BDS FACSCount™ methodology 
(Table 3.12). 
The subgroup of laboratories within his network using BDS FACSCount™ demonstrated good 
overall performance for all trials (Figure 3.26 A-D). In contrast, the performance of the BDS 
TruCOUNT™ MultiSET™ users was poor as reflected by the higher number of outlying results 
(>3.0) (Figure 3.26 E-F). One of the BDS TC/MS participants (E) had numerous problems with this 
methodology and after corrective action interventions including an investigation into the multiple 
outlying results (refer to 3.11.2) this participant generated good results from Trial 18 and all 
subsequent trials. 
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Figure 3.26: Grant supported network “A” Africa Programme. SDI values obtained from 
representative African laboratories.  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
 
 
 
 86
3.10.3.6.2  Grant supported laboratory network B 
From July 2003, grant supported laboratory network B was distributed across four countries 
including Kenya, Botswana, Uganda and Tanzania. The methodologies used by this group consisted 
of BDS TruCOUNT™ MultiSET™ with CD45 bright gating and BDS FACSCount™ methodology 
(Table 3.11). 
Once again the BDS FACSCount™ users as a group demonstrated good overall performance for all 
trials, with no outliers reported (Figure 3.27 A-D). Again and in contrast, the performance of BDS 
TruCOUNT™ MultiSET™ users was poor as reflected by the higher number of outlying results 
where there were 7 outliers with SDI values >3.0 (Figure 3.27 E-F).  
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Figure 3.27: Grant supported network “B” Africa Programme. SDI values obtained from 
representative African laboratories.  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values 
are plotted for both the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular 
laboratory. The blue arrow indicates when the laboratory enrolled on the CD4 AFREQAS scheme. 
The target SDI of 0 (red line) is indicated for comparison of data to the expected target. Represents 
outliers, while      represents non-submission for a particular trial  
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3.11 Investigation of laboratories with outlying results 
 
This included error identification with appropriate feedback and corrective action investigation 
within a SA-NHLS laboratory and an investigation of an African laboratory with multiple outlying 
results. 
3.11.1 Evidence of corrective action 
 
This included error identification (by the CD4 AFREQAS coordinator), with appropriate feedback 
and corrective action investigation within the SA-NHLS antiretroviral laboratory programme. 
 
3.11.1.1  Investigation of a laboratory with a single outlier 
A:  To monitor the longitudinal maintenance of quality through participation on CD4 AFREQAS 
scheme. 
B: To investigate a laboratory within the SA-NHLS antiretroviral laboratory programme, with error 
encountered in the generation of absolute CD4 counts. This required the investigation of 
imprecision of pipetting through the evaluation of FCR monitoring. 
1. Requested the flow count rates (FCR) to be recorded from the laboratory on 32 sequentially 
analysed samples. 
2. Two instruments were investigated with respect to FCR and absolute CD4 count 
generation. 
3. One set of a carousal of 32 samples were run, first on Epics® XL-MCL™ (XL1) and in 
second instance run on Epics® XL-MCL™ (XL2). 
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A:  To monitor the longitudinal performance of quality through participation on CD4 AFREQAS 
scheme. 
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Figure 3.28: A NHLS laboratory with an outlier on Trial 6  material run on 
Epics® XL-MCL™ (XL1) (C) for AFREQAS participation and on Epics® XL-
MCL™ (XL2) second instrument in laboratory. The X-axis is from -3 to +3 and trial 
numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both the CD4 abs 
counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates 
when the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is 
indicated for comparison of data to the expected target. Represents outliers, while      represents 
non-submission for a particular trial  
 
 
B: To investigate a laboratory within the SA-NHLS antiretroviral laboratory programme, with error 
encountered in the generation of absolute CD4 counts. This required the investigation of 
imprecision of pipetting through the evaluation of FCR monitoring. 
 
This analysis was done on 32 fresh routine samples at the laboratory (Table 3.13-3.14 and Figure 
3.29). 
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Table 3.13: Descriptive statistical results on FCR data 
 FCR (XL1) FCR (XL2) % Similarity 
Number of values 32 32 32 
Minimum 50.8 14.7 61.62 
Median 57.5 36.4 82.1 
Maximum  106.1 68.6 88.4 
Mean  58.8 37.0 81.6 
Std. Deviation 9.3 7.1 4.2 
Std. Error 1.64 1.26 0.7 
%CV  15.8 19.3 4.9 
 
Table 3.14: Outliers removed from XL1 and XL2  
 FCR (XL1) FCR (XL2) 
Number of values 32 32 
Mean  57.0 36.7 
Std. Deviation 3.3 1.64 
%CV   5.8 4.4 
 
With the outliers removed, brought the %CV’s to the acceptable %CV of 7% or less. 
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Figure 3.29: FCR sequence plot showing two pipette errors 
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Table 3.15: Explanation of outliers 
Problem encountered Reason 
Outlier on both XL1 and XL2 Error of pipetting 
Outlier on XL1 but not on XL2 Error of instrument 
Widened %CV on XL1 but not on XL2 Error of fluidics on instrument, needs 
servicing 
 
3.11.1.2 Corrective action feedback 
An outlier on CD4 absolute counts was noted on Trial 6 which fell outside the acceptable 2SD 
limits from submitted results. This SA-NHLS CD4 ARV laboratory participated on the CD4 
AFREQAS scheme. The laboratory was subsequently contacted to investigate the imprecision of 
pipetting through the validation of the FCR monitoring exercise (Table 3.13and 3.14). 
The error identified from this SA-NHLS CD4 ARV laboratory was due to imprecise pipetting 
(Table 3.15 and Figure 3.29). With corrective action feedback to this laboratory, additional training 
and operator pipetting skill validation was performed by the technologist who subsequently 
obtained a 3%CV which fell within acceptable limits. This technologist has since had a consistently 
good pipetting record as can be seen from Figure 3.28, with no outliers recorded for all subsequent 
trials. 
 
3.11.2 Investigation of a laboratory with multiple outlying results 
To aid implementation of a more reliable technology in an African site with multiple outlying 
results participating on the CD4 AFREQAS scheme. A comparative study between their predicate 
method (BDS FACSCalibur MultiSET™) versus a proposed new technology (BDS FACSCount™) 
was performed.  For this purpose, both local samples (n=43) and a panel of retrospective CD4 
AFREQAS EQA samples (n=20) for assessment of precision on CD4 abs counts and CD4%Ly for 
accuracy assessment (May-June 2006). Fresh and CD4 AFREQAS samples were prepared and 
analysed at the site using both the reference instrument and the new instrument. 
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3.11.2.1 Comparison of local samples 
Forty three fresh blood samples from the laboratory were prepared and analyses on both the BDS 
FACSCalibur™ and the BDS FACSCount™ instruments.  Samples with CD4 absolute counts 
ranging from 65.0 to 1617 were included in the study, with the majority of samples with a CD4 
absolute count of 784.0 (Table 3.16 and Figure 3.30).  
 
Table 3.16: Descriptive results of fresh samples 
 BDS FACSCalibur™ BDS FACSCount™ 
Number of values 43 43 
Minimum 65.0 72.0 
Median 784.0 717.0 
Maximum  1617 1589 
Mean  756.4 806.0 
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Figure 3.30: Scatter plots describing absolute CD4 counts obtained with BDS FACSCalibur™ 
and BDS FACSCount™ methodology on fresh blood samples.  
 
(i) Bland-Altman plot 
Bland-Altman analyses were performed to assess bias on CD4 absolute count results and determine 
agreement between two methods (BDS FACSCalibur™ and BDS FACSCount™). 
The bias between the two instruments was high (-49.6 cells/µl).  
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Figure 3.31: Bland-Altman showing bias between BDS FACSCalibur™ and BDS 
FACSCount™ CD4 enumeration.  
 
One outlier was identified as a sample with a CD4 count of 1617 (BDS FACSCalibur™) and 923 
(BDS FACSCount™), i.e. a difference of 694. With this outlier removed, the bias changed to -
67.2±86 with 95% limits of agreement -236 to 102. 
 
(ii) % Similarity sequence plot 
The percentage similarity plot was also used to assess the bias between the two methods because of 
a wide range of clinical samples tested (the % similarity smoothes the differences across a wide 
range of results). The percentage similarity value is represented in a sequence plot to identify 
outliers over the range of absolute values (Figure 3.32A). Outliers are interpreted clinically to 
ascertain if the result was clinically significant. 
Two outliers identified on the % similarity sequence plot between the BDS FACSCalibur™ and 
BDS FACSCount™ were not clinically significant (1st had a CD4 count of 482 versus 680; bias of 
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198; 2nd had a CD4 count of 1617 versus 923 with a bias of 694). Excluding this sample changed 
the mean %similarity to 104±4.6% with a %CV of 4.5% (precision of difference). 
Percentage similarity values were also represented as a Gaussian frequency distribution graph 
(Figure 3.32B). The distance of the peak from the ideal 100% similarity line (0% difference), 
indicates the bias between the two methods.  
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Figure 3.32: (A) % Similarity sequence plot indicating the ideal mean (100%) and 2 SDI limits 
(90-110%) with 2 outliers identified and (B) a frequency distribution plot. 
 
13.11.2.2  Precision analysis of existing (predicate) and proposed new methodology 
Twenty fixed whole blood CD4 AFREQAS identical samples were sent to the site for CD4 testing 
using both methods (BDS FACSCount™ and BDS FACSCalibur™) to assess precision of the 
methodologies. 
 
Table 3.17: Descriptive statistical results on fixed CD4 AFREQAS samples 
 BDS FACSCalibur™ BDS FACSCount™ 
Number of values 20 20 
Minimum 495.0 502.0 
Median 703.5 547.5 
Maximum  1275 705.0 
Mean  782.8 559.5 
 
A B
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Figure 3.33: Scatter plots describing absolute CD4 counts obtained with BDS FACSCalibur™ 
and BDS FACSCount™ methodology on fixed CD4 AFREQAS samples.  
 
Results from the fixed CD4 AFREQAS samples showed very poor correlation between 
methodologies. 
 
Subsequent to helping implement a more reliable methodology in an African site with multiple 
outlying results, participating on the CD4 AFREQAS scheme, and with ongoing corrective action 
feedback, this site is using both instruments in their routine laboratory. To date, they are 
participating on the CD4 AFREQAS scheme. Both instruments are generating good results and this 
site is a consistent good performer, testimony to the impact of participation. 
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4.0  DISCUSSION 
 
Funding for the global AIDS crisis has increased exponentially from US $260 million in 1996 to 10 
billion USD in 2007. This is nearly a forty times increase with funding coming from major AIDS 
financing institutions including the World Bank, United States president emergency plan for AIDS 
relief (PEPFAR), the global fund to fight AIDS, TB and malaria and the Bill and Melinda Gates 
Foundation (30).  
However, it is important to recognize that financial support from the developed world and charities 
for health related activities, and more specifically for laboratory capacity and infrastructure, is not 
the only solution. Africa and other third world countries must be allowed to take ownership and 
leadership in this regard (105). This requires acknowledging, from both funding agencies and 
recipients of the funding, that empowerment comes not only with funding (106). Appropriate and 
quality use of technology and adequate skills-transfer to local, district and national levels empowers 
local agencies and programmes and secures sustainable, good laboratory practice for adequate 
support of HIV/AIDS treatment programmes in a resource-poor Africa (71, 105, 107, 108).   
The World Health Organisation (WHO) African Region (AFRO) was established in 1996 to provide 
guidance, technical support and expertise in laboratory technology in the health system (109, 110) 
National reference laboratories were established through the WHO effort and given a mandate to 
ascertain the quality of CD4 testing used at their central and district laboratories of their national 
networks (111, 112). However, despite these efforts to strengthen laboratory capacity in the African 
region, challenges still remain; laboratory services need strengthening across the region. Christoph 
Larsen outlines the scenario in his recent review (108), underlined by others as well (30).  Generally 
Larson and others (71, 108, 112-114) describe the factors contributing to these challenges including 
insufficient funding, lack of national policies and plans for laboratory services, poorly trained staff, 
weak laboratory infrastructures, old and inadequately serviced equipment, lack of essential reagents 
and consumables and poor supply of support services like electricity. Where there are laboratory 
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services, very limited quality assurance including internal and external quality control are described. 
Further, the challenge facing most African countries lies in developing comprehensive national 
laboratory procedures for standardization of testing, as well as reagent and instrument procurement. 
Simplified but standardised procedures are therefore widely needed with more efficient delivery of 
supplies and instrument manufacturer support.  Acquisition through training and most especially, 
retention of skills also plays a vital role (23, 71, 108, 114). Most countries experience difficulties in 
setting up laboratories and supporting training facilities to ensure quality testing beyond basic 
training for technicians. This difficulty results in limited levels of skills available in the countries, 
with few laboratories being supervised by senior technologists and pathologists due to the brain 
drain experienced across the health sector (71, 111, 114).  
 
With the roll out of widespread treatment programmes (30, 44), CD4 testing in Africa has increased 
as well (19, 30). A quality assurance scheme is the backbone of quality laboratory testing. CD4 
lymphocyte enumeration is no different in this regard.  The need for quality testing, recognition of 
the impact of EQAS participation and feedback on improved performance of laboratories 
participating on such programmes, (15, 17, 18, 115, 116) and the absence of regional EQA 
initiatives, prompted a collaboration between the WHO and the University of the Witwatersrand. 
This initiative helped to establish a regional EQAS to nurture quality CD4 testing in the region (21, 
22). By implementing this Regional African External Quality Assessment Scheme, namely the CD4 
AFREQAS (21) quality of CD4 testing in the region could be assessed and potentially improved, 
using the EQAS as platform to help identify specific skills deficiencies of laboratory CD4 testing 
(in individual laboratories or across national laboratory networks) and establish structures for 
further training (21, 22). To build further capacity, the CD4 AFREQAS additionally implemented 
structures for setting up African national EQAS networks in countries (21).This tiered approach to 
decentralise distribution of EQA in the region, enables interested African countries to actively 
participate in the delivery of their local EQAS (taking ownership of their national EQAS) whilst 
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being supported under the regional AFREQAS umbrella. Five country programmes were 
established and supported in this way including South Africa, Botswana, Namibia, Lesotho and 
Zimbabwe. Zambia, Ghana, Nigeria, Swaziland Kenya and Malawi have subsequently expressed 
interest and requested CD4 AFREQAS support for development of their national EQA programmes 
as well. Other non-country networks have also joined the CD4 AFREQAS initiative including 
clinical study (grant based) groups like the International Vaccine Initiative (IAVI) and United States 
president emergency plan for AIDS relief (PEPFAR).  
 
The performance of established methods and technologies and how these technologies are used in 
the hands of experienced personnel, largely in the first world, has been established (28, 84, 104, 
117-120). Although there are numerous one-off validations comparing a multitude of CD4 
technologies in an African setting (52, 121, 122), Only a handful of publications review actual 
between-laboratory precision and review overall performance of African CD4 laboratories (21-23).  
The establishment of the AFREQAS offered a unique opportunity to review the quality of CD4 
testing not only of individual African laboratories but within groups of laboratories using the same 
CD4 technology as well as noting the performance across national schemes (relatively under- 
resourced) or other networks (relatively well resourced grant supported groups).  This performance 
could either be assessed at specific time points (i.e. within a single trial and be comparable to a 
single multi-centre validation of laboratories) or the pooled data used retrospectively to review 
longitudinal cumulative performance. Such analysis offered insights into the manner in which 
African laboratories use (effectively or not) different CD4 technologies and/or methods over time 
and what kind of problems typically hinder implementation and delivery of quality services.  
 
During 20 trials of CD4 AFREQAS over a period of 4 years, the overall participation rate was 
excellent with average 91.8% participation and an average non return rate of 8.1%, testament to 
established recognition by regional participants of the need for quality assessment (19, 30, 71, 107, 
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111, 112, 114, 123). Overall, reasons for non-submission of results were consistent with the 
findings of Larsen (Appendix C Table 3.18). These included lack of basic essential equipment, staff 
shortages and poor technical skills, lack of laboratory consumables and reagents, the lack of 
supplier and vendor availability for support and maintenance of equipment, use of incorrect pipettes 
and lack of instrumentation for calibration, unreliable power supplies, and poorly developed 
communication transport and custom clearance infrastructure. Amazingly, a dead donkey also lead 
to failure of submission of results in a single Zambian site!  (See Appendix D1, supplementary data 
for details of other reasons for non-submission of results).  
The average precision of all participants overall, across 20 trials, was noted to be 11.9CV% for 
absolute CD4 counts and 10.8CV% for CD4%Ly reporting. This performance is similar to the 
overall precision (%CV) reported on the UK NEQAS scheme across 23 trials (from January 2001 to 
February 2005) of 13.1CV% absolute CD4 counts and 13.4CV% for CD4%Ly reporting (here, the 
UK NEQAS scheme had a response rate of 89.7%) (93).  The National Institute of Allergy and 
Infectious Disease (NIAID) Division of AIDS Quality Assurance (QA) Programme has further 
reported similar improved precision over a two year period (82).  Details of precision within 
specific trials can be seen in Table 3.6.  
 
Participation on the CD4 AFREQAS scheme has improved individual and between- laboratory 
variation and identified problems experienced by participating laboratories; the findings are very 
similar to findings reported in other studies (17, 18, 24, 115). Sometimes dramatic (worsened) 
changes in the precision were noted when new participants joined the programme, which 
subsequently returned improved to previous levels of precision of the group when these new 
participants became more experienced (see Figures 3.6-3.8). Such reduction in %CVs over a 9-year 
period precision (%CV) was previously reported by UK NEQAS (17), for absolute CD4 values 
from 15 %CV to <5 %CV (17). Health Canada (QASI) has also shown a decrease in precision 
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(%CV) over five surveys, decreasing from 7.2% to 4.7% and from 14.2% to 8.8% for CD4%Ly and 
absolute CD4 counts, respectively (18).  
Two levels of CD4 count material were shipped in most CD4 AFREQAS trials (see Table 2.1 for 
details). With the “normal” and “low” value CD4 EQA material, similar findings were reported in 
other studies (17, 18), with overall  poorer precision with “low” count material than “normal” count 
material been noted amongst CD4 AFREQAS users. For “normal” count material 10.9% and 8.1% 
for CD4 abs and CD4%Ly was noted and for “low” count material 14.2% and 17.0% for CD4 abs 
and CD4%Ly was noted (Figure 3.4). 
 
The precision between laboratories, overall and within groups of laboratories participating on the 
same trial is shown in Figures 3.6-3.8. 
As reported in previous studies (58, 120, 124) the BDS FACSCount™ group showed very good 
between-laboratory precision with a  mean %CV of <7% noted over twenty trials (Figures 3.6, 3.8, 
3.9A, 3.10, 3.12). In only one trial (Trial 3) was poor precision seen, with a 13%CV noted. This was 
due to one instrument failing and requiring a service. Post servicing of this instrument, for all 
subsequent trials, the precision of the group remained excellent below <10%CV (Figure 3.6). 
Overall accuracy and precision was also excellent as evidenced by the tight Mean SDI and narrow 
SD (of the Mean SDI) noted in the retrospective longitudinal analysis (Figures 3.9, 3.10, 3.12). This 
excellent performance was maintained irrespective of whether “normal” and “low” material was 
used; %CV of 5.8% and 6.4% were recorded respectively across 20 trials.  Of note especially, this 
excellent performance was noted across all networks, irrespective of origin (noted overall across all 
FACSCount™ users and that within country- or grant-supported networks).  
One error however, common to several FACSCount™ users, was the incorrect submission of 
CD4% of T cells results instead of the clinically required CD4%Ly values (noted in 16% of 
FACSCount submitted results).  This problem has been attended to by the manufacturers, BDS, and 
improvements (i.e. new FACSCount™ software for CD4%Ly and absolute CD4 counts) have been 
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released and validated (125). Another occasional error was related to incorrect pipetting and/ or the 
use of poorly calibrated pipettes, also reported elsewhere (58). In this instance, the impact of advice 
given to improve pipetting skills by focusing on within-laboratory precision of individual 
technicians or advice on calibration of pipettes proved to be invaluable to these laboratories.  
 
There was evidence of several problems related to use of TruCOUNT™/MultiSET™ (TC/MS) 
algorithm based method (also from BDS) from as early as Trial 1, with poor performance noted 
intermittently across 20 trials. The poor precision amongst this group was evident both within single 
trials (Figures 3.6-3.8) as well in the retrospective analysis of pooled SDI data (Figures 3.9B, 3.10, 
3.11, 3.13, 3.14, 3.21E-H, 3.24D-F). Contributing to the poorer precision of this group was the 
dramatic increase of participants (89%) who joined the scheme between Trials 9 and 12. This 
increase in participants corresponded with a dramatic fall of precision between these users during 
this period.  Here the precision (%CV) between laboratories reporting TC/MS-generated absolute 
CD4 counts fell from <10% to 26%, suggesting that most new users enrolled between Trials 9 and 
12 were not sufficiently trained and largely unfamiliar with the TC/MS technology they were using. 
During feedback, most new TC/MS participants reported unfamiliarity with the MultiSET software 
and inability to manipulate the gating and algorithm. Further application training was advised in 
order for laboratory staff to adequately apply the algorithm and perform appropriate and necessary 
gating. Attention to pipetting precision was also found to be contributing to the poor between-
laboratory precision.  In this instance, advice given to improve pipetting skills by focusing on 
within-laboratory precision of individual technicians (skilled reversed pipetting a necessity) as well 
as advice on calibration of pipettes proved to be invaluable to these laboratories. Bead rate 
monitoring (84, 98) was also advised for ongoing within-laboratory quality monitoring. By trial 16 
(~7 months later) the impact of additional training and feedback was noted with precision between 
laboratories using the TC/MS system once again falling in line with expected performance (104) 
and returning to the pre-Trial 9 TC/MS between-user precision of ~10CV%, remaining as such until 
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Trial 20. The findings of the TC/MS users highlights the learning effects per trial of participation 
and that corrective action interventions are proportional to the time of participation on the CD4 
AFREQAS scheme (17, 18, 24, 115). Interestingly, in spite of relatively better resourced 
laboratories and access to training, laboratories participating within the grant-supported networks 
also did not do well as a group. This finding highlights the fact that investment in training cannot be 
over emphasized and that algorithm systems, although sold as “automated” systems, still require 
training and insight for adequate operation (21).  
 
Impact of feedback during EQAS participation was demonstrated in the context of performance of 
the FACSCount™ and TC/ MS™ users as a group. In one instance, specific advice was offered to a 
participating laboratory whose current predicate method was TC/MS™ but whose performance had 
been consistently poor with majority of results falling outside of 2SD of the pool mean (Figure 
3.26.E). The participating laboratory was subsequently advised to switch over from their predicate 
TC/MS™ system to the FACSCount™ system if they wished to improve reproducibility and 
accuracy of their clinical reporting. Although a bias of -49.6cells/µl noted between methods in the 
validation switch study performed for the site (Figures 3.30- 3.32), the site was nonetheless advised 
to switch from TC/MS to FACSCount™ for their routine testing to ensure more reliable CD4 
enumeration by the laboratory in the long run. This decision was made based on the marked 
improvement of precision noted when using the FACSCount™ system (Table 3.17, Figure 3.33). 
The site was further advised to notify their attending clinicians of the implications of a one-off bias 
in reporting CD4 and the implications on treatment related decisions.  The value of training was 
strongly emphasized and included improving pipetting skills by focusing on the within-laboratory 
precision of individual personnel and accurate calibration of pipettes, as well as understanding and 
use of the MultiSET™ software for correct gating technique. This intervention proved to be 
invaluable to this site. From Trial 21, the impact of feedback and additional training was noted: this 
site has used both methodologies in the laboratory to date and has subsequently become a consistent 
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reliable performing site, with all submitted results being within 2 SD of  the trial pool mean, for 
both their TC/MS™ and FACSCount™ systems (data not shown). 
 
Analysis of performance of groups using specific gating strategies supported published data 
showing that laboratories who use CD45 bright (lymphocyte) gating perform for CD4 enumeration 
do better than laboratories who do not (82, 115, 126). Data from the AFREQAS TC/MS™ group 
who used a CD8/CD4/CD45/CD3 protocol with CD45 bright gating (126) performed better 
(14%CV and 20.8% CV for absolute CD4 counts and CD4%Ly respectively) than those 
laboratories that used CD3/CD4/CD8 with primary CD3 gating (127) for analysis (precision of 
21.4%CV and 41.7CV% was noted for absolute CD4 counts and CD4%Ly respectively). This 
highlights the importance of adherence to international guidelines (2, 128)  when such systems are 
used.  As noted within their BDS counterparts (i.e. the FACSCount™ user group), these 
participants also incorrectly reported CD4% of CD3+ T cell values instead of the required 
CD4%Ly. These results were identified as outliers and in turn affected the precision of the group 
(Figures 3.6, 3.9A, 3.10, 3.12). Although frequently after feedback, some laboratories understood 
the difference of reporting and no longer reported CD4% T cells in error, other continued to 
incorrectly submit the CD4% T cells values. 
 
The laboratories using the SP PLG-CD4 method with manual gating showed overall very good 
between-laboratory precision, with an average %CV of <9% for absolute counts and <5% for 
CD4%Ly noted over the period of participation (Figures 3.6-3.8). This precision has been shown in 
other studies (28, 72, 118, 129). The proactive use of bead count rate monitoring with the PLG-CD4 
method helped to ensure reliable between-laboratory precision (84, 98). In addition, a major 
contributing factor was that the PLG-CD4 users were given ongoing supportive training by the SA-
NHLS CD4 reference laboratory and Beckman Coulter South Africa. This training included on-site 
and off-site workshop training, consolidated into website based and opportunities for hands on 
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training in an established accredited facility reference laboratory (130).  The excellent performance 
of this group highlights and emphasises the importance and value of use of proactive quality control 
and ongoing consolidated training support for laboratory personnel (23, 84) in ensuring sustainable 
quality of CD4 reporting. Similar excellent within and between laboratory precision of laboratories 
using SP PLG CD4 has been reported as far afield as the Caribbean (72). 
Some minor problems that occurred included incorrect gating protocol (not the standardised NHLS 
protocol), incorrect reporting of CD4% of the white cell count result instead of reporting a 
CD4%Ly and occasional transcription errors. With corrective action intervention, all problems were 
easily rectified. Most especially of note with the SP PLG-CD4 method was the consistent reliable 
precision of CD4%Ly values reported by these users. Although CD3 is not included in the protocol 
to identify T cells and exclude monocytes as is used in other T cell enumeration methods (46, 128, 
131, 132), the excellent precision of the users in this group confirms existing reports that show that 
CD4 and side scatter measurement (without CD3) is sufficient to identify CD4 lymphocytes and 
adequately exclude contamination with monocytes (53, 118, 133-135).  
The impact of  CD4 AFREQAS feedback to a SA-NHLS laboratory with a single outlying result 
caused largely by pipette error is noted in Figure 3.20C. Here, corrective action feedback, 
consolidated with the integrated system of initial site validation (99), proactive quality control (84, 
96) on-site and offsite workshop training in an established accredited facility reference laboratory 
(136),  website based training (130) has made a huge impact on excellent CD4 service delivery of 
the NHLS laboratories in South Africa (84).  
 
In contrast to the guideline based TC/MS also using CD45/3/4/8 with algorithm based analysis, a 
small group of BC Flow-Count™TetraONE™ users showed consistently good performance, similar 
to that noted elsewhere in a multi-site study (119). Despite manual gating used by these sites, across 
the twenty trials, no problems encountered with this method and there were no outlying results 
noted (Appendix D). However, all the sites were within South Africa and had direct access to 
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training within the National Health Laboratory Service from the Johannesburg NHLS Reference 
laboratory, as well as access to training from Beckman Coulter South Africa. Once again, this 
emphasizes the importance of the role of training and insight into testing, as well as manufacturer 
support, in the delivery of quality CD4 testing. 
 
Although the number of users was small, as a group, the laboratories using the Volumetric 
counting/ methodology from Partec® method did not perform well. This group showed generally 
poor between-laboratory precision across 20 trials with an average precision (%CV) of 27% noted 
for absolute CD4 count reporting (Figures 3.6, 3.8). Evidence of problems within the Partec® user 
group was initially evident on review of this group’s within trial precision (%CV) on individual 
trials (Figures 3.6, 3.8). The poor precision of these Partec® users as a group was further confirmed 
through the retrospective cumulative analysis of the pooled SDI results of the group over 20 trials 
(Figures 3.9D, 3.23C-H, 3.24 G-H). Compounding the poor performance, the number of Partec® 
participants increased by 43% during Trials 18 and 19, corresponding with a dramatic fall of 
precision between these users during this period.  Here the precision (%CV) between laboratories 
reporting absolute CD4 counts fell from <13% to 34% suggesting that most new users enrolled 
between Trials 18 and 19 were not sufficiently trained and largely unfamiliar with the technology 
they were using. During feedback, most new Partec® participants reported that they had received 
little training and technical support from the Partec® manufacturers. Although it was acknowledged 
that access to training was difficult for these users, further training was strongly advised to improve 
quality in these laboratories. Attention to pipetting precision was found to be one of the contributing 
factors leading to the poor between-laboratory precision.  In this instance, advice was given to 
improve pipetting skills (once reverse pipetting for accurate volumetric testing) by focusing on 
within-laboratory precision of individual technicians (practicing pipetting water and blood) as well 
as calibration of pipettes, especially necessary in the context of volumetric testing. However this 
proved to be a problem as some laboratories did not have basic laboratory equipment.  For example 
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a basic analytical balance was lacking at most sites for validating pipettes. Further bead rate 
monitoring (98) was also suggested as a further additional internal quality control of pipette error 
(although technically the Partec system uses volumetric methodology and does not require beads, 
BCR monitoring was suggested purely to monitor pipetting error). All advice, unfortunately, had no 
impact on performance.  By trial 20, (~2 months later), precision (%CV) of this group continued to 
be much worse than the overall global precision of the pool of users, with an average precision of 
28%CV noted. Some sites recognised the need to swop technologies and after a period of poor 
performance and consultation with CD4 AFREQAS, one site changed their method to the BDS 
FACSCount™ (with consequent excellent precision performance on the CD4 AFREQAS scheme 
noted with other FACSCount™ users). This again highlights that systems with minimal training 
requirements can facilitate delivery of good results in settings where training resources are limited.  
Typically, these instruments, especially the low end models, are not able to generate CD4%Ly 
values. In this group, 3.3% of users incorrectly reported CD4% of T cells results instead of the 
clinically relevant values CD4%Ly results. As noted with participants of the CD4 AFREQAS using 
either FACSCount™ and TC/MS™ using primary CD3 gating, laboratory personnel using Partec® 
equipment do not know the difference between required CD4%Ly values and the CD4% of T cells 
reported on a Partec®. Appropriate corrective feedback helped to ensure that this error was not 
repeated. The problems related to use in a resource poor setting has been noted by others. In a study 
done by Lynen L. et al it was demonstrated that it was imperative that intensive training of the staff 
was conducted to obtain reliable results (137). Another study done by Pattanapanyasat K et al 
showed that technical training was an absolute requirement for accurate CD4 counting (56). In 
Malawi, local laboratory staff reported that the Partec® instrument procedures simple to run and the 
instrument easy to operate after training .  Others have reported that bead calibration of volumetric 
testing is crucial to ensuring precision and accuracy of these instruments (54, 121).     
Overall, the participants using this volumetric method were unable to match the performance of the 
technology reported elsewhere (117) However and in striking contrast, the performance of a 
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preference laboratory participating from Germany was excellent. This laboratory had requested 
joining the CD4 AFREQAS programme as a reference site for two Mission Hospitals it supported 
in Africa. Excellent within-laboratory performance was noted from this German laboratory 
(Appendix D supplementary data), once again confirming that insight into instrument operation and 
knowledge of maintenance procedures is of vital importance in ensuring optimal performance of the 
technology.   
 
The number of dual platform users was small (7%) amongst the CD4 AFREQAS users, with 
varying levels of precision was noted.  Those laboratories that received good technical support, and 
training from respective suppliers or within their network, showed good precision performance 
across the trials. As with the group using the equivalent single platform system, the group using the 
Beckman Coulter DP TetraONE™ (CD45/4/8/3) users who received good technical support and 
training, were sites within South Africa that had direct training within the National Health 
Laboratory Service and access to training from Beckman Coulter South Africa. These sites 
outperformed those African laboratories who did not receive the support, once again emphasising 
the importance training and manufacture support in the delivery of quality CD4 testing.  
However, and once again, laboratories who did not receive the support and training performed less 
well. Laboratories that used traditional DP testing but with abbreviated panels or algorithm based 
automated software (MultiSET™) for analysis performed less well (Appendix D supplementary 
data). Problems that contributed to this poorer performance included use of total lymphocyte count 
in the traditional DP system, a known variable parameter in the calculation of absolute CD4 counts 
between laboratories (2, 127, 128). Others reported difficulties with gating and manual overriding 
of algorithm software with use of MultiSET™ software. 
The best performance amongst the group of laboratories using dual platform methodology was 
shown with amongst the DP Panleucogated (PLG-CD4) users where no outliers were noted across 
20 trials. The improved precision PLG-CD4 method despite a DP format, is based on established 
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good precision of white cell counts between laboratories (2, 83, 134, 135) and avoids use of the 
conventional guideline based Total Lymphocyte count used in traditional DP testing (132). Here, as 
reported elsewhere (117), individual laboratory performance and precision between laboratories, 
was shown to be equivalent to that noted with single platform testing.  
 
A retrospective statististical analysis was performed comprising all individual standaridised SDI 
results, pooled across 20 trails, to assess mean SDI of laboratories grouped according to the CD4 
methodology used (21) (Figures 3.10- 3.15). The three most commonly used methodologies over 
the twenty trial are analysed  using this model (Figures 3.10- 3.15),  including the BDS 
FACSCount™, the BDS TC/MS™ and SP PLG-CD4 user groups. In contrast to the precision 
(%CV) within individual trials where data was trimmed (Figures 3.6-3.7), this retrospective analysis 
includes all results, as well as outliers, to give an overview on the true precision between 
laboratories using the CD4 methodology. It further facilitates insights into how CD4 technologies 
are used, which technologies are best used, how much error is associated with a use of particular 
technology and further, based on the latter, what the training needs are. As mentioned previously, 
the mean SDI demonstrates longitudinal accuracy and the SD (of the Mean SDI) gives an idea of 
long term and ongoing precision. The group of laboratories that showed a mean (SDI) close to 0 and 
SD (Mean SDI) within the range of 0 - 1 were demonstrated to have the best accuracy and 
precision. In this analysis, two groups emerged: one group showing laboratories with tighter 
between laboratory precision suggesting less additional training needs (predominated by 
FACSCount™, SP PLG-CD4 and DP PLG-CD4 users) and a second group showing laboratories 
with wider between laboratory variations with more training needs (predominated by users of 
TC/MS technology) . The details of this analysis can be seen in (Figures 3.10- 3.15). 
As confirmed in the individual trial analysis where within trial precision of the group was excellent 
(Figure 3.9A and C), the laboratories using the BDS FACSCount™ technology as well as the SP 
PLG-CD4 user group showed mean SDI values close to 0 and SD SDI values within the range of 0 - 
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1, indicating that these laboratories were able to consistently submit reliable and accurate results. 
Confirming the poorer performance of TC/ MS users noted trial by trial (Figure 3.9B) the 
laboratories within the BDS TC/MS group performed less well and showed a wider variation of 
results. Although this group showed acceptable average accuracy, the spread of the data within the 
SDI range, as reflected by the SD (Mean SDI), confirmed the overall poorer precision of this group 
(with  ±Mean SDI range falling between 1 - 2).  
 
In response to internal and external pressure to combat HIV/AIDS, the South African government 
released its Operational Plan for the Comprehensive HIV and AIDS Care, Management and 
Treatment for South Africa in November 2003 (138, 139). In support of this programme, there are 
currently more than 70 SA-NHLS laboratories offering CD4 enumeration SA-NHLS has 
standardised CD4 testing with the simpler SP protocol (PLG-CD4). The excellent performance of 
this network in comparison with other groups on the CD4 AFREQAS, has been ensured with use of 
novel proactive internal quality control, viz. BCR monitoring introduced to exclude pipetting errors 
(84, 98), together with active training programmes including workshops organised by the NHLS 
Johannesburg Reference laboratory, as well as website training access (130). Despite the need for 
some operator input and use by personnel with little or no flow cytometry background, notably the 
performance of this group compares well with the excellent performance of the FACSCount users 
as a whole (where minimal input is required from the operator).   
Namibia also has standardised CD4 testing across five national health laboratories to SP PLG-CD4 
following the implementation of their national ARV treatment programme. Across the trials, the 
performance of the standardised SP PLG-CD4 participants was good but not as impressive as the 
South African NHLS laboratory network. As noted in the SA-NHLS programme, occasional 
outlying values were due to incorrect reporting of CD4% of WBC and/ or the occasional inaccurate 
gating. Here, performance of the Namibian PLG network (Figure 3.22 A-F) suggests that these 
laboratories require additional training with a focus on pipetting precision and use of bead count 
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rate monitoring to improve internal quality control (98) if they are to match the performance of their 
South African counterparts. Occasional non submission of results was due to personnel shortages; 
problems of increased staff turnover were frequently reported.  
 
Problems of a similar nature were noted across the Botswana, the Lesotho and the Zimbabwe 
national networks. Most notably, the lack of standardisation across all three programmes has 
impacted negatively on the overall performance of these national networks. BDS TC/MS CD45 
bright gating system was used in laboratories in all three countries and the performance was 
generally inconsistent and poor. Similar to sites across the region, and in South Africa, factors 
contributing to the poorer precision included poor understanding and application of the automated 
algorithm software especially related to gating and manual identification of relevant populations 
seen (Figures 3.21 A-H, 3.23 A-B, 3.24 D, 3.26 E-F, 3.27 E-F). The Partec® system was 
additionally used in Lesotho and Zimbabwe and both national network laboratories showed poor 
precision with this methodology (Figures3.23 G-H, 3.24 G-H). The main contributing factor was 
the lack of training on use as well as limited maintenance and repair of instruments. In spite of 
corrective action feedback, the Lesotho and Zimbabwean national programmes continued to show 
wide variability of CD4 results many trials later. Of note however, and in stark contrast within these 
three networks, is the excellent performance of FACSCount™ users (Figures 3.21A-D, 3.24 A-C, 
3.26 A-D, and 3.27 A-D). Here, once again, even though the same logistical difficulties and other 
political and economic circumstances were present at these sites, the laboratories within the 
networks using FACScount ™ markedly outperformed their counterpart laboratories, showing 
excellent between –laboratory results.  Zimbabwe was especially affected by local politics and dire 
economic circumstance where four otherwise excellent performing FACSCount™ sites were unable 
to submit results for several trials. Other major problems reported from sites across either 
Zimbabwe, Botswana or Lesotho involved numerous breakdowns following the installation of 
equipment. Poor instrument manufacturer maintenance and service delivery and lack of funds or 
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human resource further contributed. In Botswana and Zimbabwean participants also reported major 
problems with reagents with short shelf life and/or receipt of expired reagents often due to slow 
customs clearance. In contrast to the South African network, the most obvious differences noted in 
Namibia, Lesotho, Botswana and Zimbabwe were the lack of active training initiatives and 
standardization. Use of systems like the BDS FACSCount™ or alternatively, SP PLG methodology 
with supportive training coordinated through the South African NHLS, could significantly reduce 
between laboratory precision in Lesotho, Botswana and Zimbabwe, as noted previously on the 
South African NHLS network (84), the Brazilian programme (124) or in the Caribbean (72).  
 
Although considerably better resourced than their African counterpart laboratories, similar 
performance of laboratories was observed within the grant supported laboratory networks as that 
seen in the African national networks. From August 2003, grant supported laboratory network “A” 
sponsors has been in collaboration with African partners to collect epidemiological data and to build 
capacity for large-scale clinical trials on HIV/AIDS (140). These trials are taking place in four 
countries, including Kenya, Rwanda, Uganda and Zambia and further include several trial sites. 
From July 2003, grant supported laboratory network, designated “B”, acted with US agencies to 
build capacity for large-scale clinical trials on HIV/AIDS focusing on the interventions to prevent 
HIV transmission. These trials are taking place across nine sites in four countries including Kenya, 
Botswana, Uganda and Tanzania. 
The performance of these grant-supported networks was reviewed to demonstrate that similar issues 
and problems emerge within African networks, irrespective of resources and funding. Once again,  
problems emerge that are largely due to lack of training and instrument maintenance as well as lack 
of technical support and trained staff leaving because of recruitment of other companies or 
international posts being available. Neither of networks had standardised methodologies in place.  
During feedback, participants using the TC/MS system also reported unfamiliarity with the 
MultiSET™ software and inability to manipulate the gating and algorithm. Attention to pipetting 
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precision was also found to be contributing to the poor between-laboratory precision. FACSCount 
users, as in other African networks, as a sub-group, demonstrated excellent performance for all 
trials. None of the US based grant networks used PLG CD4. 
 
In summary, outliers identified on the CD4 AFREQAS scheme were investigated by the AFREQAS 
coordinator to help laboratories resolve problems with methodology and/or technical issues. The 
advantages and strengths of all methods have been demonstrated in this study. The improvement in 
CD4 reporting found in this study and others (22, 23, 84), confirms that African laboratory 
technicians are able to use simpler flow cytometry systems that require minimal training or operator 
input when internal quality controls are in place (28, 58, 84, 120). These include, most notably the 
BDS FACSCount™ that can be used with automatic pipetting in a low to medium volume 
throughput laboratory with minimal training or the cost effective SP PLG-CD4 method with a 
capacity for high volume throughput of CD4 tests per day but requiring some training in flow 
cytometry and pipetting skills. BDS TruCOUNT™MultiSET™ and Partec® methods have 
demonstrated poorer between and within-laboratory performance on the CD4 AFREQAS scheme. 
However, the benefits of training and manufacturer support, as well as the use of proactive quality 
control systems (58, 84, 96, 98, 99, 120, 124, 130, 141) were clearly demonstrated to have an 
impact on improving the performance of laboratories using these systems. 
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5.0 CONCLUSION 
 
The aim of the study was to implement a regional CD4 EQA scheme ( CD4 AFREQAS), not only 
to assess performance of participating laboratories but to provide a platform for improving 
reproducibility of CD4 reporting both within- and between-laboratories in South Africa and Africa. 
Further CD4 AFREQAS has provided ongoing teaching through participant feedback evaluation 
and dedicated training programmes, as well as advocated the use of standardised laboratory 
protocols necessary to contain costs and maintain high standards of CD4 testing.  
 
With universal access to ARV therapy in Africa, the demand for CD4 testing is on the increase. 
This study has demonstrated that African laboratories do understand that participation in CD4 
AFREQAS can highlight deficiencies in their laboratories. Improvement of performance following 
corrective action advice and improved quality of their CD4 service delivery in their respective 
countries is evidence supporting the impact of corrective action feedback. Further, the performance 
of specific networks within the region (31) has shown that African countries can benefit from 
implementation of standardised national strategies and plans to support CD4 testing and monitoring. 
In South Africa especially, through the integrated system of the CD4 AFREQAS scheme, and the 
use of corrective action feedback, together with on-site and offsite workshop training in an 
established accredited facility reference laboratory all consolidated into website based training, the 
impact of standardization is noted and precedent set for establishing excellent CD4 service delivery 
in an African setting. Guidelines on standardisation of CD4 (and other laboratory testing) in Africa 
could play an important role in scaling up and establishing excellent service delivery in the region. 
 
This study has confirmed previous reports and firmly establishes which factors contribute to poor 
performance and has further highlighted which technologies are best used in an African setting. 
However, investment in additional technical training and support from the flow cytometry 
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manufacturers cannot be over emphasized. Education of laboratory personnel will ultimately secure 
and help to sustain service delivery and improve the quality of CD4 testing in the region.  
 
The success of the CD4 AFREQAS scheme is highlighted by the fact that from 195 participants at 
the end of Trial 20, it had grown to more than 500 registered participants by early 2009. In addition 
the scheme obtained SANAS (South African National Accreditation System) accreditation in 
August 2008, so that it conforms to international standards. Therefore the CD4 AFREQAS scheme 
offers African participants a scheme which is accredited, and internationally recognised as being on 
a par with schemes such as the UK NEQAS. The difference with the CD4 AFREQAS scheme is 
that it offers assistance with additional training and corrective action support. To conclude, the 
scheme has been widely accepted by African participants who have found that the CD4 AFREQAS 
scheme can help them to implement a better service.   
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Documentation required for the CD4 AFREQAS scheme   APPENDIX B: 
 
Registration form         APPENDIX B1 
 
 
 
 
 
CD4+ Lymphocyte Proficiency Programme 
2009 
A new registration form is to be completed for participation in 2009 
  IMPORTANT: Please put your participant code on the form if you  
   Already have one.                                                             
REGISTRATION FORM-PARTICIPANT CODE: 
Pathologist:  
Phone No:  
Fax No:  
e-mail address:  
 
Flow Analyst: Contact Person in the laboratory: 
Phone No:  
Fax No:  
e-mail address:  
 
Mailing Details: 
Physical Address: IMPORTANT FOR COURIER DELIVERY 
Laboratory Name:  
Institution:  
Room Number: 
Floor Number: 
 
Department:  
Street:  
City:  
Postal Code:  
  
Postal Address:  
Laboratory Name:  
Institution:  
Department:  
PO Box:  
City:  
Postal Code:  
The 2009 registration form is for continued participation and to update records.  
FAX OR E-MAIL BACK TO HAZEL AGGETT AT: 
FAX: +27 11 386 6296 
E-MAIL: hazel.aggett@nhls.ac.za 
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Participant unique code number:      APPENDIX B2 
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Certificate of participation:       APPENDIX B3 
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Laboratory Safety:        APPENDIX B4 
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 Instructions:         APPENDIX B5 
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Export permit:        APPENDIX B6 
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Commercial invoice:        APPENDIX B7 
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Import permit:        APPENDIX B8 
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Result sheet:         APPENDIX B9 
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Participant performance report:     APPENDIX B10 
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Permission to quote Professor C Larsen’s paper:     APPENDIX C 
Summary of problems and strategies for accessible support in the least developed countries 
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APPENDIX C1 
 
Summary of problems and strategies for accessible support in the least developed countries 
(Extracted with permission from Christoph H Larsen. The fragile environments of inexpensive CD4+T-cell enumeration in the 
least developed countries: Strategies for accessible support. Cytometry Part B Clin Cytrom 2008; 74B:S107-S116). 
 Problems encounted Strategies and solutions 
THE CHAOTIC 
LANDSCAPE OF AID 
 
 Health care remains weak due to 
chronic under funding of their primary 
health systems. 
Multiplicity of donors has created 
parallel infrastructures that are 
difficult to manage and undermine the 
responsibilities of public health 
services. 
Compromised the sustainability and 
implementation of ART and CD4 
enumeration. 
Internal and external brain drain. 
Lack of funds for modern technology, 
maintenance and human resource 
development. 
Need for more efficient operations, 
where reductions in unit costs are 
associated with increased numbers of 
tests and higher profits. 
Simplified technology with increased 
reliability with affordable laboratory 
involvement. 
HARDWARE ISSUES  
Procurement The procurement of high value 
equipment is guided by non-technical 
interests with mixed results. 
No ascertainable information available 
on novel instrumentation on 
performance, reliability and field 
installation requirements to obtain 
optimal results. 
Instrument manufactures to streamline 
production. 
Simpler flow cytometers with smaller, 
cheaper and less power hungry lasers. 
Reduce pipetting steps as pipettes 
require regular calibrations and most 
sites do not have analytical balances. 
 
Instrument support Most installations operate without 
service contracts or protective shields 
after the one year warranty is up. 
Sustainability of equipment is under 
threat. 
Rental agreements linked to service 
support. 
Modular bay design with pluggable 
tubing and wiring that can be 
exchanged in the case of malfunction 
could avoid costly shipping of entire 
pieces of equipment. 
Enviromental factors Dust exerts a detrimental effect on 
equipment. 
Need costly air-conditioning. 
Refrigeration needs electricity or fuel 
supplies. 
Unreliable power supplies causes 
damage to equipment. 
Power variations cause secondary 
damage to equipment and loss of 
production hours. 
Knocks sustained during instrument 
transport over poorly developed 
infrastructures causing misalignments 
of lasers. 
Dust proof casing to reduce the 
number of dust-related incidents and 
service visits. 
Require a fast switching power supply 
with a range of 70-280 V 
Assisted with a professional surge 
protector. This setup is capable of 
providing adequate power 
conditioning for a wide range of 
environments including erratic mains, 
solar and battery/inverter combination 
supply settings. 
POST-SALES ISSUES  
Reagent supplies Poorly developed communication, 
transport and customs clearance 
infrastructure. 
Accounting procedures are 
restrictive. 
Advanced payment requirements. 
Reagent rental agreements. 
A pay-as-you-go pricing concept 
absorbs the total cost of 
ownership, including training, 
maintenance, repairs and reagent 
shipping. 
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Shipping and custom clearance is 
slow. 
Ordered from outside the end-
users country. 
 Relatively short shelf life. Shipped 
reagents are time consuming. 
Perishable supplies require a 
constant cold chain with extra 
charges incurred. 
Expired reagents: the end-user 
incurs the cost if there is no 
contract agreement. 
Long life reagents are required. 
Lyophilised reagents tend to have 
extended shelf life. 
Reagents should be heat stable and 
not require a cold chain facility. 
Benefits of less frequent ordering. 
Service visits Simple repairs may be done in one 
visit. In more severe cases a 
second visit is required after 
ordering spare parts. 
Laboratory staff tends to have 
problems mobilizing funds, 
followed by pre-payment causing 
long down-time. 
Sipping and customs clearance 
create further delays. 
Simpler flow cytometers designed 
as desktop units with less need for 
laser adjustments. 
Remote instrument diagnostics 
and trouble-shooting technological 
innovations have rendered 
internet-based, a realistic and cost-
efficient option. 
Corporate service 
management 
Main focus is on nurturing 
resource-rich environments. 
The end-users in poor settings are 
commonly serviced by stripped 
down versions of support systems. 
Web-based customer-relationship 
management and enterprise 
resource planning software is 
expected to ease the existing 
complex communication and 
logistic issues. 
A public-private partnership is 
proposed that involve government, 
manufactures and local 
distributors with field application 
specialists. 
Human resources HIV/AIDS is taking its toll among 
health workers resulting in 
increased staff turnover. 
Poor staff retention in 
dysfunctional working 
environments, with inadequate 
support, missed salaries and 
cursory attention to staff 
development. 
Resignation of senior staff as no 
successors are trained even in 
basic maintenance procedures. 
The health care workforce needs 
to be trained and supported to be 
committed. 
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SUPPLEMENTARY DATA       APPENDIX D  
 
 Longitudinal performance of individual laboratories      APPENDIX D1 
Longitudinal performance was graphically represented by plotting sequential SDI results from a 
specific participating laboratory on circular (radar) plots. This would reflect the accuracy and 
precision of testing over time. These radar plots demonstrated when a particular laboratory joined 
the CD4 AFREQAS scheme, instances when there were outlying results or where there were no-
submission of results, showed when interventions improved performance, as well as overall 
accuracy and precision. 
Performance with change of methodology could also be monitored. The selection of laboratories is 
representative of the performance across many participants which were specially chosen to 
represent either ideal performance or typical problems encountered through participation. 
 
BDS FACSCount™ user precision 
 
Across the twenty trials the BDS FACSCount™ users showed consistently good performance and 
this is shown on the graphical radar SDI performance of representative participants (Figure 3.34, 
Table 3.18). The minor problems that occurred were easily rectified with the help and advice given 
to the participants.  
 
The performance of laboratories A, B and C is typical of the general performance of BDS 
FACSCount™ users on CD4 AFREQAS, showing consistently good performance across all trials. 
Laboratory D enrolled on the programme from Trial 2 and poor performance was reflected in an 
outlying result with an SDI exceeding 3.0. Consequently after corrective feedback and advice, the 
BDS FACSCount™ instrument in this laboratory was serviced and this participant became a 
consistent good performer for all subsequent trials. Laboratory E had one outlying result and overall 
a consistent performer. Laboratory F did not submit a result due to an unfortunate incident which 
occurred at their customs office containing the shipped samples. The parcel was destroyed by 
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custom officials as a 9/11 security procedure. There were two major problems that occurred with 
two other laboratories. Laboratory G joined the programme from Trial 6 showed consistent 
excellent results across nine trials, reflecting general performance of BDS FACSCount™ users. 
However, in the subsequent trials (16-20) this participant could not send in results due to problems 
with the instrument and a 6 month wait for repairs. Laboratory H joined the programme from Trial 
6 and for four trials generated excellent results. However, in the next four trials the poor 
performance generated outlying SDI values >3.0. Initially, quality had been failing on this 
instrument and after numerous suggestions the problem was still not solved. This participant 
decided to change methodology to BDS TruCOUNT™/MultiSET™ on FACSCalibur instrument. 
Unfortunately, despite changing methodology, there was no improvement in the laboratory’s overall 
performance.  
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BDS FACSCount™  users A-G 
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Figure 3.34: Representative selection of laboratories using BDS FACSCount™ methodology (A-H). BDS 
FACSCount™ is unable to generate CD4%Ly values and only abs counts with respect to submission is shown 
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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BDS TruCOUNT™/MultiSET™ users  
Across the twenty trials the BDS TC/MS users showed poorer performance than BDS 
FACSCount™ users and this is shown on the graphical radar SDI performance of representative 
participants (Figure 3.35 3.36, Table 3.18) 
 
 Performance (precision) of laboratories using CD45 bright gating strategy 
Across the twenty trials the performance of the users using CD45 bright gating showed a wider 
variation of submitted results. This is shown on the graphical radar SDI performance of 
representative participants (Figure 3.35 A-H) (Table 3.18). The irregular patterns noted are 
representative of the poorer precision and accuracy of some of these users, and this would be 
mainly attributed to poor understanding and application of the automated algorithm software of 
manually gating. 
The performance of Laboratory A is typical of the performance of a laboratory using CD45 bright 
gating. Laboratory B showed adequate accuracy but the precision was erratic across all trials. 
Laboratory C enrolled on the programme from Trial 8 and for six trials used SP PLG CD4 method 
and performed well. From Trial 14 onwards this site changed to CD45 bright gating because this 
laboratory received an excellent instrument and reagent deal from the suppliers. This site was a 
consistent performer, having mastered a change of methodologies very well. Laboratory D enrolled 
on the programme from Trial 9 and for three trials did not submit results. No explanation was given. 
Subsequently, showed adequate accuracy but the precision was erratic across all trials. The poor 
performance of Laboratory E was reflected by the number of non submission of results and outlying 
results. Laboratory F, enrolled on the programme from Trial 3 and on four different trials the 
laboratory generated outlying results with SDI values of >3.0. On trial 16 this participant did not 
send in a result. In consultation with this participant it was revealed they had their FACSCalibur 
serviced and the staff received technical training. Reflective of training, this site became a 
consistent good performer for all subsequent trials. Laboratory G showed poor precision on the abs 
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counts and better precision for CD4%Ly. Laboratory H joined the programme from Trial 6 where 
performance was adequate. However, from Trial 10 to Trial 13 this laboratory’s performance (SDI 
values of >3.0) deteriorated  This participant decided to changed methodology from BDS 
FACSCount™ to BDS TruCOUNT™/MultiSET™, from Trial 14 their performance did not 
improve. In communication with this site, it transpired that they had experienced problems in 
getting additional training on their instrument and software applications and they were also 
concerned about their pipettes. Advice and help was given on pipetting techniques and validation of 
pipettes. Subsequently, the site received additional training from BDS on their instrument and 
software applications. Since Trial 20 their performance has improved dramatically reflecting the 
impact of appropriate interventions.  
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BDS TC/MS CD45 bright gating, A-G 
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Figure 3.35: Representative selection of laboratories using BDS TC/MS CD45 bright gating methodology 
(A-H).  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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Performance (precision) of laboratories using primary CD3 gating strategy 
Across the twenty trials laboratories using primary CD3 gating showed a wide variation of 
submitted results. This is shown on the graphical radar SDI performance of representative 
participants (Figure 3.36 A-H) (Table 3.18). The poor performance was reflected by a high number 
of outlying results (>3.0) with an outlier rate of 21.6%. The irregular patterns noted are 
representative of the poorer precision and accuracy of some of these users, and this would be 
mainly attributed to poor understanding and application of the automated algorithm software of 
manually gating. Primary CD3 gating were prone to incorrectly report lymphocyte percentages, 
CD4% of T cells (as a consequence of Primary CD3 gating) was frequently incorrectly reported 
instead of the required values.  
Laboratory A performed better than Laboratory B. All the CD4 absolute counts were within the 2 
SD range. They incorrectly reported CD4% of T-cell values and as a consequence had three 
outlying results. Laboratory B showed the same problems experienced by Laboratory’s A. Another 
laboratory in South Africa, Laboratory C had endless logistical and staff problems from Trial 3 to 
Trial 12, having experienced a high turnover rate of technologist. From Trial 13 new management 
was put into place and the laboratory took up the suggestion to employ skilled personnel, training as 
well as implementing additional staff motivation programmes. From Trial 13 to Trial 20 the 
laboratory’s performance had substantially improved reflecting the impact of training.  Laboratory 
D had been given initial training on the FACSCalibur by the supplier BDS. No results were 
submitted from Trial 16 to Trial 18 as the instrument required a new part. The instrument was 
subsequently repaired by the BDS service engineer. After being repaired, the laboratory still sent in 
results over the 2 SD limits for both abs counts and CD4%Ly. To-date, this site changed gating 
methodology to CD45 bright gating and their performance had improved (data not shown). 
Laboratory E, incorrectly reported CD4%Ly from Trial 3 to Trial 17 by reporting CD4% of T cells 
(as a consequence of Primary CD3 gating).The poor performance was reflected by this high number 
of outlying results (>3.0). However, for abs counts, all their results submitted fell within the 2 SD 
 136
range. This site did do all the necessary maintenance, pipette validation and regular servicing of the 
FACSCalibur. It was also recommended by Beckton Dickinson, the supplier, to change to CD45 
bright gating as this method is more reproducible. The site reported that poor performance and 
problems with using primary CD3 gating was also reflected in their under performance on the UK 
NEQAS Scheme. The laboratory did take the advice and change methodologies to the 
recommended four colour CD45 bright gating. From However from Trial 19, and on all subsequent 
trials (data not shown) this laboratory did became a good and consistent performer.  
Occasionally participants experience problems with both abs counts and CD4%Ly reporting 
Laboratory F joined the CD4 AFREQAS programme from Trial 10 and from this trial to Trial 20 
demonstrated poor performance with respect to both abs counts and CD4%Ly results. This was 
unfortunately a high through-put laboratory generating CD4 results for patients on ARV treatment. 
It was suggested that they change gating methodology to the four colour CD45 bright gating 
strategy. However the laboratory indicated that they thought that the CD4 AFREQAS material was 
the problem and did not respond to corrective actions. This laboratory was closed down by their 
management after Trial 20. Laboratory G is an example of a site that needed manufacturer input and 
training. From registration on Trial 10, and all subsequent trial, this site had problems with abs 
counts and CD4%Ly, as well as non submission of results. This site was a poor performing site and 
only after Trial 20 did this site change to CD45 bright gating strategy and improved on their 
performance (data not shown). Laboratory H is an example how continued ongoing corrective input 
and switching to CD45 bright gating can improve performance of participating laboratory 
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BDS TC/MS Primary CD3 gating, A-G 
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Figure 3.36: Representative selection of laboratories using Primary CD3 gating methodology (A-H).  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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SP PLG-CD4 user precision 
Across the twenty trials the performance of the participants using SP PLG-CD4 users showed 
consistently good performance and this is shown on the graphical radar SDI performance of the 
representative participants (Figure 3.37 A-H, Table 3.18). SP PLG-CD4 methodology generated 
outlying results (SDI values of >3.0) for abs counts of 5.4% and CD4%Ly of 3.1%. The minor 
problems that occurred included manual gating, incorrect reporting of CD4% of WBC and 
transcription errors. These were easily rectified with the help and advice given to the participants.  
 
Laboratory A is representative of a consistently good performance across twenty trials. Laboratory 
B joined the programme from Trial 1 and for five trials demonstrated excellent performance using 
DP PLG CD4 methodology. From Trial 6 this site changed to single platform and remained a 
consistently good performing laboratory, demonstrating the ease of transition of a laboratory using 
PLG from dual platform to single platform methodology. Laboratory C is representative of a 
consistently good performance across twenty trials. Laboratory D is representative of a consistently 
good performance across twenty trials. Laboratory E had an outlier on their first trial, Trial 6. It was 
noted that the pipettes were never calibrated and were subsequently calibrated and from Trial 7, the 
results were well within the 2 SD limits. Participant F had one outlier while they participated on the 
AFREQAS programme, and this was due to incorrect reporting %CD4 of white cells instead of 
reporting a %CD4Ly values. Typically, this type of error did not reoccur after corrective action 
intervention. Laboratory G and H each had a single outlying result in Trial 1 due to submitting low 
absolute CD4 counts on “normal” value material. This error was due to incorrect gating protocol. 
After corrective action, these two laboratories remained consistent god performers. What was 
especially noted with SP PLG CD4 method was the consistent reliable precision of CD4%Ly values 
reported by these users. With the use of CD45 bright and side scatter PLG protocol, monocytes are 
excluded from the CD4 lymphocyte population and excellent precision reported. 
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All SP PLG-CD4 
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Figure 3.37 Representative selections of laboratories using SP PLG-CD4 methodology (A-H).  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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Partec® user precision 
Across the twenty trials the performance of the participants using Partec® showed a wider variation 
of submitted results in which a vast majority of results fell outside the 2 SD acceptable range. The 
poor performance was reflected by the high number of outlying results of abs counts (31.9%). 
This is shown on the graphical radar SDI performance of the representative participants (Figure 
3.38 A-H, Table 3.18).  The irregular patterns that are shown demonstrate poorer precision and 
accuracy of individual users. The main problem observed with these users was the lack of training 
and maintenance of instruments at these sites. There was an overall average rate of 27.4% noted 
across the 20 trials of non submission of results due to down time of these instruments. 
 
Overall, the participants using this volumetric method did not perform well. A reference laboratory 
from Germany, Laboratory A, supported two Mission Hospitals in Africa. The performance of this 
laboratory was good, suggesting that there is no obvious incompatibility of the performance with 
Partec® instruments. The Partec® users did get initial training on the instruments when they were 
placed in the laboratories. However follow-up training and service delivery was poor as evidenced 
by the performance of Participants B and C (Figure 3.8). Participant B, their first submitted result 
on joining was within the 2 SD limits but on subsequent trials, Trial 10 to Trial 20, this laboratory 
had problems with the Partec® instrument and the submitted results fell outside the 2 SD limits. On 
Trial 19 the trimmed SDI value was 23.1. With ongoing corrective action feedback, Participant B 
changed their method to the BDS FACSCount™ and has since shown to be an excellent participant 
on the CD4 AFREQAS scheme. Laboratory C is a participant who struggled to get maintenance and 
repairs for the instrument after it was placed in their laboratory. The suppliers did give the 
laboratory training on the instrument when they placed the instrument in the laboratory. At one 
stage the instrument was out of order for four months and the laboratory could not generate CD4 
counts for patients. Medecins Sans Frontiers (MSF) supported laboratories in southern rural districts 
of Thyolo and Chiradzulu and the central district of Dowa in Malawi. They placed Partec® Cyflow 
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instruments into these sites but before getting them installed asked the CD4 AFREQAS programme 
about the instrument. They took it upon themselves to get intensive training to all their supported 
sites. Laboratory D is one of the sites and has been a consistent good performer since joining 
AFREQAS from Trial 18 and all subsequent trials (data not shown). Once again, emphasizing the 
importance of instrument maintenance, training and manufacturer support. 
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Partec® users A-H 
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Figure 3.38: Representative selections of laboratories using Partec® methodology (A-H). Partec® 
methodology is unable to generate CD4%Ly values and only abs counts with respect to submission is shown 
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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Dual platform user precision 
Participant C from Zimbabwe enrolled on the programme from Trial 5 and from Trial 8 the 
laboratory had outliers and no submission of results. This is a laboratory that had no technical and 
financial support and used expired reagents. Both the Haematology analyzer and FACSCalibur 
could not get serviced due to the financial constraints of the laboratory. However, Participant D 
from South Africa had very good technical support and training from the respective suppliers and 
showed to be a good performing participant. 
Participants E and F (figure 3.39) enrolled on the programme using dual platform primary CD3 
gating and changed to single platform four colour CD45 bright gating strategies. Participant E was a 
poor performer even after changing methods. This laboratory received training from the suppliers 
but could not grasp the technology. They subsequently closed down due to financial constraints. 
Participant F is an example of continued ongoing corrective input to bring performance of 
laboratory using Dual platform Primary CD3 gating in line with expected performance of 
TruCOUNT™/MultiSET™ CD45 bright gated CD3/CD4/CD8. 
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DP PLG-CD4 users A-B 
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DP BDS MultiSET™ Primary CD3 gating with/4/8 changed to single platform Trucount™ evaluation 
E-F 
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
1A
1B
2A
2B
3
4
5
6
7
8
9
10A
10B
11A11B12B13A
14A
14B
15A
15B
16A
17A
17B
18A
18B
19A
20A
20BE
   
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
1A
1B 2A
2B
3
4
5
6
7
8
9
10A
10B
11A11B12B13A
14A
14B
15A
15B
16A
17A
17B
18A
18B
19A
20A 20B
F
 
DP TetraONE™ CD45 bright gating CD3/4/8 users G-H 
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
1A
1B
2A
2B
3
4
5
6
7
8
9
10A
10B
11A11B12B13A
14A
14B
15A
15B
16A
17A
17B
18A
18B
19A
20A
20B
G
   
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
1A
1B
2A
2B
3
4
5
6
7
8
9
10A
10B
11A11B12B13A
14A
14B
15A
15B
16A
17A
17B
18A
18B
19A
20A
20B
H
 
Figure 3.39: Longitudinal SDI follow-up performance of a selection of laboratories using dual platform 
systems 
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on theCD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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Beckman Coulter system TetraONE™ and FlowCount™ user precision 
Across the twenty trials the performance of the laboratories showed consistently good performance 
using TetraONE™ FlowCount™ with CD45 bright gating. This is shown on the graphical radar 
SDI performance of representative participants (Figure 3.40 A-H). There were no problems 
encountered in laboratories using this technology on the CD4 AFREQAS programme and no 
outlying results were encounted across twenty trials. However, it is important to mention that all the 
sites were within South Africa and had direct access to training within the National Health 
Laboratory Service and access to training from Beckman Coulter South Africa. Once again this 
emphasises the importance of the role of training and manufacturer support in the delivery of 
quality CD4 testing. 
 
All Laboratories (A-H) showed consistently good performance. Laboratory F joined AFREQAS 
from Trial 3 and changed technology to SP PLG CD4 from Trial 10. This was due to the 
laboratory’s participation in an ARV programme in Kwa -Zulu Natal in which SP PLG CD4 offered 
the more cost effective method in line with the NHLS National ARV programme. Participants G 
and H used this technology for a clinical trial study which was implemented from Trial 17 and both 
abs counts and CD4%Ly showed very good performance for all four trials and subsequent trials 
(data not shown). 
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Beckman Coulter system TetraONE™ and FlowCount™ A-H 
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Figure 3.40: Representative selection of laboratories using Beckman Coulter SP TetraONE™ CD45 bright 
gating (A-H).  
The X-axis is from -3 to +3 and trial numbers are indicated from 1A to 20B on the Y-axis. SDI values are plotted for both 
the CD4 abs counts (Blue) and CD4%Ly values (Green) for a particular laboratory. The blue arrow indicates when 
the laboratory enrolled on the CD4 AFREQAS scheme. The target SDI of 0 (red line) is indicated for comparison of data 
to the expected target. Represents outliers, while      represents non-submission for a particular trial          Represents 
change of methodology 
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SUPPLEMENTARY DATA     APPENDIX D 2 
 
 
Table 3.18: Summary of problems identified and corrective actions for CD4 AFREQAS 
participants 
Figure Trial 
number 
Methodology Problems identified Corrective action 
interventions 
Within trial precision of African laboratory networks 
3.20 
 
20 
(Number A) 
South Africa (NHLS) 
SP PLG CD4 
Trial 20 isolated outlier. 
Transcription error. 
Incorrect reporting %CD4 of 
WCC. Corrected in subsequent 
trials (data not shown).  
 6 
(Number C) 
South African (NHLS) 
SP PLG CD4 
First trial low results 
submitted. 
Corrective solutions offered. 
FCR exercise done (Section 
3.11). Subsequent results were 
within ±2SDI. 
 18A 
(Number F) 
South African (NHLS) 
SP PLG CD4 
From trial 6 to 20 only 
one result out due to 
transcription error. Trial 
10 no %CD4 of 
lymphocytes reported. 
Laboratory forgot to write 
in result.  
Laboratory identified problem. 
Subsequent results were within 
±2SDI. 
3.21 
 
4/10/14/15 
(Number E) 
Botswanan  (NGL)  
BDS TC/MS CD45 bright 
gating 
 
Low results submitted for 
four trials. Participant 
needs to acquire skills for 
manual gating. 
Corrective solutions offered 
including, to receive technical 
training by BD on manual gating 
as protocol is automated. 
 
 16/25/30 
(Number E) 
Botswanan  (NGL)  
BDS TC/MS CD45 bright 
gating 
 
Non submission of results 
as instrument out of 
order. Requested advice 
on improving results. 
BD did training at laboratory. 
From Trial 17 results were 
within ±2SDI. Great 
improvement noted.  
 15-20 
(Number G) 
Botswanan  (NGL)  
BDS TC/MS CD45 bright 
gating 
 
Non submissions and 
outlying results.  
Corrective solutions offered 
including suggested software 
application and training by BD 
as well as pipette calibration and 
pipette technique training 
 15-20 
(Number H) 
Botswanan  (NGL)  
BDS TC/MS CD45 bright 
gating 
 
Non submissions. 
FACSCalibur not 
working. Laboratory 
could not fix the problem 
Suggested contacting BD. 
3.22 
 
 (Number A-E) Namibian (NIP) 
SP PLG CD4 
Three of Namibia’s 
laboratories had problems 
of non submission of 
results as well as low or 
high absolute counts. 
Non submission of results was 
due to internal laboratory staff 
problems. Subsequently sorted 
out and results sent back in time 
for analysis. Wrong absolute 
counts were due to pipetting 
errors. Need to introduce 
monitoring of FCR. Namibia has 
as yet not done so. 
3.23 
 
14-15 
(Number A) 
Lesotho (NGL) 
BDS TC/MS CD45 bright 
gating 
In two out of seven trials 
no results were submitted. 
Three trials results were 
>±2SDI. 
Corrective solutions offered 
including suggesting software 
application and training by BD 
as well as pipette calibration and 
pipette technique training.  
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 14-16 
(Number B) 
Lesotho (NGL) 
BDS TC/MS CD45 bright 
gating 
Two out of seven trials no 
submission of results. 
Four trials results were 
>±2SDI. 
Corrective solutions offered 
including software application 
and training by BD, changing to 
CD45 bright gating as well as 
pipette calibration and pipette 
technique training. After Trial 20 
this site did not improve. 
 14-16/19/20 
16/19/20 
14-20 
15-20 
14-20 
(Number C-h) 
Lesotho (NGL) 
Partec instruments® 
All laboratories using 
Partec® had problems 
with non submission and 
low absolute count 
results. Instruments 
frequently down with 
little support. 
As a corrective solution, 
suggested to get basic 
maintenance and repair training 
on the Partec® as well as 
technical training. The same 
problems have continued after 
trial 20. Little improvement in 
submitted results for all sites. 
3.24 
 
20 
(Number B) 
Zimbabwe (NGL)  
BDS FACSCount™ 
One result with low 
absolute count. 
To monitor BDS FACSCount™ 
as there was an isolated outlier. 
This site had continued 
procurement issues wit many 
non submissions. 
  (Number D) Zimbabwe (NGL) BDS 
TC/MS CD45 bright 
gating 
Low and high results 
submitted. 
As a corrective solution, 
suggested software application 
and training by BD on manual 
gating to enable participant to 
override automated software as 
required. Erratic results and non 
submission of results continued 
post trial 20. 
  (Number E) Zimbabwe (NGL)  
Dual platform TC/MS 
CD45 bright gating 
Low absolute count 
values submitted for all 
trials. 
Corrective solutions offered 
including software application 
and training by BD as well as 
pipette calibration and pipette 
technique training. Haematology 
analyser also needed servicing. 
Problems in getting it serviced. 
  (Number G) Zimbabwe (NGL)  
Partec instruments® 
Low absolute count 
values submitted. 
Laboratory decided the 
instrument needed a service as 
the laboratory had inherited the 
instrument. However, could not 
get it serviced due to no support 
from Partec® 
Within trial precision of grant supported laboratory networks 
3.26 
 
10-12 
(Number D) 
Grant supported network 
“A” 
BDS FACSCount™ 
For the first three trials 
non submission of results. 
No reasons given for non 
submissions. 
From subsequent trials all results 
were within ±2SDI. Laboratory 
performed very well on the 
AFREQAS programme. 
 9-17 
(Number E) 
Grant supported network 
“A” 
BDS TC/MS CD45 bright 
gating 
From Trial 9 -17 had 
major problems with the 
technology. 
Did validation study to assist 
laboratory. See validation report 
(Section 3.11.2). 
Laboratory showed consistent 
good performance with BDS 
TC/MS CD45 bright gating and 
new method BDS FACSCount™ 
 9-20 
(Number F) 
Grant supported network 
“A” 
BDS TC/MS Primary CD3 
Had problems of non 
submission of results and 
when results were 
Corrective solutions offered 
including suggesting technical 
training by BD, changing to 
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gating submitted the 
performance was outside 
of 3SD. This laboratory 
required more training. 
CD45 gating. Post Trial 20 this 
laboratory started to perform 
better. Results not shown. 
3.27 
 
10-12 
(Number B) 
Grant supported network 
“B” 
BDS FACSCount™ 
Initial three trials non 
submission of results. 
Laboratory staff was still 
in training when the 
laboratory registered on 
AFREQAS. Hence the 
delay in submission of 
results.  
All subsequent trials results were 
within ±2SDI. 
 10/19 
(Number C) 
Grant supported network 
“B” 
BDS FACSCount™ 
Two trials non 
submission of results. Not 
satisfied with results, did 
not send them in. All 
other trials results were 
within ±2SDI. 
This laboratory did not require 
corrective intervention. 
Explained to this site that non 
submission of results was 
unacceptable on participation in 
an EQA scheme. Shows poor 
performanceofalaboratory. 
 15-17 
(Number D) 
Grant supported network 
“B” 
BDS FACSCount™ 
Three trials non 
submission of results. 
Laboratory was not 
satisfied with instrument. 
Instrument serviced after a long 
delay. After the service, all 
results were within ±2SDI. 
     
General problems encounted in countries 
Senegal University laboratory 
BDS FACSCount™ 
Customs security alert. 
USA 9/11 terrorist attack. 
No samples received. 
No intervention required. 
Tanzania Private laboratory 
Guava PCA 
Non submission of results 
for all trials. 
Laboratory discontinued 
their participation with 
CD4 AFREQAS. 
Laboratory did not respond to 
corrective solutions offered. 
Ivory Coast University R/D laboratory 
BDS TC/MS CD45 bright 
gating 
Initial non submission of 
results. Laboratory could 
not get parcel through 
customs. 
Custom service required 
AFREQAS Export Permit 
in French as well as 
English. 
After numerous telephone calls 
to customs department and 
Home affairs in Ivory Coast a 
French export permit was 
granted to the CD4 AFREQAS 
programme. This site has since 
shown to be a consistent good 
performer. Very good results 
submitted using BDS TC/MS CD45 
bright gating. They mastered this 
methodology. 
Burundi University laboratory 
DP  BDS TC/MS Primary 
CD3 gating 
Six submitted results over 
fifteen shipments 
received. 
Major problems with custom 
clearance. CD4 AFREQAS 
could not help the laboratory to 
sort out the logistics involved. 
This is a continuing problem that 
the participant needs to sort out. 
From Trial 20, the custom 
clearance issue had not been 
resolved. 
Angola Military Hospital 
Laboratory 
DP  BDS TC/MS Primary 
One submission from 
sixteen trials. 
CD4 EQA material went 
Government and political 
interference. The laboratory was 
given permission to receive the 
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CD3 gating through customs. Results 
could not be submitted. 
CD4 EQA material by the 
Military department but was not 
allowed to submit the results to 
CD4 AFREQAS. The 
department would not give a 
reason for non submission. 
Subsequent to Trial 20 the 
laboratory discontinued 
participation. 
Kenya Mission Hospital 
BDS FACSCount™ 
Three trials non 
submission of results. 
In consultation with the 
participant, the lack of power 
supply to the laboratory was the 
reason for non submission of 
results. No corrective 
intervention could be given. 
However, when results were 
received these were <2SD. 
Ghana Private laboratory 
BDS FACSCount™ 
Three trials non 
submission of results. 
This was due to problems 
with custom clearance. 
AFREQAS addressed the 
problem with the relevant person 
at customs and the courier 
company. Subsequent shipments 
passed through customs 
smoothly. Subsequent results all 
within <2SD. However, CD4 
results within the 2SD though. 
Zambia Small District Hospital  
Laboratory 
SP PLG CD4 
Three trials non 
submission of results. 
Rats ate cables of phone 
and fax lines. 
Cables had to be ordered from 
South Africa with further delays. 
No corrective intervention could 
be given. 
 Private laboratory 
BDS TC/MS CD45 bright 
gating 
Three trials non 
submission of results. 
The lack of power supply 
to the laboratory was the 
reason for non submission 
of results. 
Laboratory installed back-up 
generator. Submitted results 
were erratic. As a corrective 
solution, suggested software 
application and training by BD 
on manual gating to enable 
participant to override automated 
software as required. Erratic 
results and non submission of 
results continued post trial 20. 
 Mission Hospital 
Partec instruments® 
One trial non submission 
of results. The donkey 
passed away. CD4 
AFREQAS parcel could 
not get to remote Mission 
Hospital in time for 
submission of results. 
A scooter has replaced the 
donkey. However, performance 
was marred by other factors 
including no support to service 
instrument. Waited for spare 
parts. This problem continued 
after Trial 20. 
Botswana Private laboratory 
BDS FACSCount™ 
Two trials non 
submission of results. 
Cleaning staff signed for the two 
deliveries and placed the parcels 
in the broom cupboard and 
forgot about them. In-house 
problems have been sorted out. 
Subsequent results all within 
<2SD. Excellent performance 
shown. 
 Private laboratory 
BDS FACSCount™ 
Four trials non 
submission of results. 
AFREQAS explained the 
importance of participation. 
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Laboratory did not think 
it was important to submit 
all results timeously. 
Results for all subsequent trials 
were received on time. Very 
good performance shown. 
Longitudinal SDI performance of individual laboratories over time 
3.34 
 
2A-2B 
(Number D) 
BDS FACSCount™ High absolute 
counts. SDI>3.0 
Instrument serviced. 
From Trial 3 
performance was 
improved. 
 19A 
(Number G) 
BDS FACSCount™ One result SDI>-3.0 
Isolated outlier. 
No corrective 
action. Good 
performing 
laboratory. 
 15A-17B 
(Number H) 
BDS FACSCount™ Non submission of 
results for three 
trials. No support to 
service instrument. 
Waited for spare 
parts. 
No corrective action 
required. From Trial 
18 consistent good 
performing 
laboratory. 
3.35 
 
4/5/11/20 
(Number E) 
BDS TC/MS CD45 
bright gating 
Non submission of 
results for four trials 
and two trials had 
high absolute CD4 
counts. 
Suggested technical 
training by BD. 
Laboratory thanked 
AFREQAS for 
showing interest 
and would 
troubleshoot their 
problems. 
Performance 
improved 
 14A-14B 
(Number F) 
BDS TC/MS CD45 
bright gating 
High absolute 
results submitted. 
Suggested 
instrument service 
and technical 
training by BD. 
 16 
(Number F) 
BDS TC/MS CD45 
bright gating 
No results 
submitted.  The 
laboratory could not 
fix instrument. 
FACSCalibur 
service and repair 
advised. Results 
from Trial 17-20 
within ±2SDI. 
 10B-13 
(Number H) 
BDS FACSCount™ FACSCount 
generated high 
counts for three 
trials. Could not get 
the FACSCount to 
give correct control 
values. 
Changed 
technology to 
TruCOUNT™/MultiSET
™. Advised the 
participant to get 
technical training 
by BD. 
 
 14-20 
(Number H) 
BDS TC/MS CD45 
bright gating 
Changed 
technology from 
FACSCount from 
Trial 14. Had 
problems from Trial 
14-20. 
Again suggested 
technical training 
by BD with pipette 
calibration and 
pipette technique 
training. 
3.36 
 
3/11B14B 
(Number A) 
BDS TC/MS Primary 
CD3 gating 
Lymphocyte % 
results low on three 
trials. 
Laboratory did not 
respond to 
corrective solutions 
offered. 
 2B/10A/13A BDS TC/MS Primary Four trials low Suggested 
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(Number B) CD3 gating results submitted.  calibrating pipettes 
or changing to 
CD45 bright gating. 
Calibrated pipettes. 
The laboratory 
monitored 
performance. 
Changed 
technology to CD45 
bright gating 
Improved 
performance. 
Results within 
±2SDI. 
 3-12B 
(Number C) 
BDS TC/MS Primary 
CD3 gating 
For ten trials 
laboratory 
submitted high 
results. Endless 
logistical and staff 
problems. High 
staff turnover. 
Suggested technical 
training by BD as 
well as pipette 
calibration and 
pipette technique 
training. 
 13-20B 
(Number C) 
BDS TC/MS Primary 
CD3 gating 
From Trial 13 all 
subsequent results 
were within ±2SDI. 
New management, 
new staff. Took up 
suggestion of 
training and 
motivating staff. 
 16A-20B 
(Number D) 
BDS TC/MS Primary 
CD3 gating 
From Trial 16 no 
submitted results 
and SDI results 
>±3. National 
logistical and 
financial 
difficulties. 
Corrective solutions 
offered, suggested 
changing to CD45 
bright gating. Trial 
21 changed to 
CD45 bright gating 
and subsequent 
results were within 
±2SDI (data not 
shown). 
 5-20B 
(Number E) 
BDS TC/MS Primary 
CD3 gating 
From Trial 5 had 
problems with 
CD4%Ly.  
Corrective solutions 
offered, suggested 
changing to CD45 
bright gating. No 
action taken. 
Withdrew after Trial 
20. 
 3-17B 
(Number E) 
BDS TC/MS Primary 
CD3 gating 
From Trial 3 
submitted results 
that were very high 
or extremely low. 
Also had problems 
with UKNEQAS 
programme. 
Corrective solutions 
offered including 
changing to CD45 
bright gating. Trial 
18 changed to 
CD45 bright gating 
and subsequent 
results were within 
±2SDI. 
 10A-20B 
(Number F) 
BDS TC/MS Primary 
CD3 gating 
From joining 
AFREQAS very 
high results 
submitted. 
Laboratory did not 
respond to 
corrective solutions 
offered. 
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Laboratory 
concluded the CD4 
EQA material was a 
problem. 
Management 
stopped routine 
CD4 testing in this 
laboratory. 
 10A-20B 
(Number G) 
BDS TC/MS Primary 
CD3 gating 
From joining 
AFREQAS had 
submitted very 
erratic results. 
Skilled staff 
shortages. 
Multiple corrective 
solutions offered 
including changing 
to CD45 bright 
gating. For ten trials 
no intervention 
helped. 
Subsequently, 
changed to CD45 
bright gating. 
Improved 
performance from 
trial 20 results not 
shown. 
3.37 
 
6 
(Number E) 
SP PLG CD4 First trial low 
results submitted. 
Calibrated pipettes. 
Subsequent results 
were within ±2SDI. 
 12B 
(Number F) 
SP PLG CD4 From trial 3 to 20 
only one result out. 
Isolated outlier. 
Transcription error. 
Incorrect reporting 
%CD4 of WCC. 
Corrected in 
subsequent trials. 
 15A-B 
(Number G) 
SP PLG CD4 Low results 
submitted. SDI >-
3.0 
Checked pipetting 
technique. 
Subsequent results 
were within ±2SDI. 
 6 
(Number H) 
SP PLG CD4 Low absolute count 
submitted. SDI >-
2.0 
Checked pipetting 
technique. 
Subsequent results 
were within ±2SDI. 
3.38 
 
10A-20B 
(Number B) 
Partec instruments® Seven of the twelve 
trials results were 
very high or 
extremely low. Had 
training on first 
submission. 
Thereafter, no 
support. 
Corrective solutions 
offered. Suggested 
basic maintenance 
and repair training 
as well as technical 
training. 
 17A-18B 
(Number C) 
Partec instruments® Non submission of 
results for two 
trials.  
No support to 
service instrument. 
Waited for spare 
parts. 
 20A-B 
(Number C) 
Partec instruments® High absolute CD4 
counts submitted. 
Corrective solutions 
offered. Suggested 
technical training. 
Subsequently 
changed technology 
to SP PLG (Trial 
21) with successful 
performance. 
 Prior 18 
(Number D) 
Partec instruments® Asked advice 
before installation 
of instrument 
All subsequent 
results were within 
±2SDI. 
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